Cap 139N s 3 Presence of prohibited chemicals in food animals十二

合集下载

precption英语作文

precption英语作文Perception.Perception is the process of taking information through our senses and organizing and interpreting it to form a meaningful representation of the world around us. It is a complex process that is influenced by a variety of factors, including our past experiences, expectations, and beliefs.There are two main types of perception:Sensory perception is the process of taking in information through our senses. This includes sight, hearing, smell, taste, and touch.Cognitive perception is the process of organizing and interpreting the information that we take in through our senses. This includes making sense of the world around us, recognizing objects, and understanding speech.Perception is a highly subjective process, and no two people perceive the world in exactly the same way. This is because our perceptions are influenced by our own unique experiences, expectations, and beliefs.How Perception Can Be Influenced.A number of factors can influence our perception, including:Our past experiences: Our past experiences can shape our expectations and beliefs about the world, which can in turn influence our perception of new experiences. For example, if you have had a bad experience with a certain type of animal, you may be more likely to perceive all animals of that type as dangerous.Our expectations: Our expectations can also influence our perception. If we expect something to happen, we are more likely to perceive it when it does. For example, if you are expecting to see a friend at a certain place and time, you may be more likely to notice them when theyarrive.Our beliefs: Our beliefs can also influence our perception. If we believe something to be true, we are more likely to perceive it as being true. For example, if you believe that the world is a dangerous place, you may be more likely to perceive threats where there are none.Implications of Perception.Our perception of the world has a significant impact on our behavior. The way we perceive the world influences our decisions, our relationships, and our overall well-being.For example:If we perceive ourselves as being capable, we are more likely to set challenging goals and take risks.If we perceive others as being trustworthy, we are more likely to form close relationships with them.If we perceive the world as being a safe place, we are more likely to feel happy and content.Conclusion.Perception is a complex and fascinating process that plays a vital role in our lives. It is influenced by a variety of factors, including our past experiences, expectations, and beliefs. Our perception of the world hasa significant impact on our behavior, our relationships,and our overall well-being.中文回答：感知是通过我们的感官获取信息并对其进行组织和解释的过程，以形成对我们周围世界有意义的表征。

美国社区儿童肺炎治疗体系 Community-Acquired Pneumonia

In the US, there is substantial variation across hospitals and physicians in diagnosis, treatment, and outcomes.
Kronman MP. Pediatrics. 2011; Shah SS. J Hosp Med. 2011; Lee GE. Pediatrics. 2010; Shah SS. Pediatr Pulmonol. 2010
TM
Why Do We Need Guidelines?
Role of guidelines
o Assist in healthcare decision-making o Reduce variation in clinical practice o Lead to better patient care and outcomes
Samir S. Shah, MD, MSCE, FAAP
Professor, Department of Pediatrics University of Cincinnati College of Medicine Director, Division of Hospital Medicine Cincinnati Children's Hospital Medical Center
Strength of Recommendation (Strong or Weak)
Quality of Evidence (High, Moderate, or Low)
TM
Evidence-Based Guidelines
Clinical Recommendations

危险物品接受检查清单-2009说明书

Returned to shipper using DOT-SP 14691Due to the regulatory discrepancies indicated, your shipment cannot be transported by FedEx.Tracking Number ___________________________________________ Date ______________________________________________________ Inspected By ______________________________________________ Emp # ____________________________________________________ For Dry Ice shipments, refer only to the shaded items (e.g., 1).1. □If international shipments (Form 400 series), ensure SRGshows “D” designation.2. □If 023 air waybills, correct statement(s) in the HandlingInformation box, as appropriate. [8.2.1; 8.2.3]3. □Complies with all applicable government and FedEx variations.[2.9.2; 2.9.4]4. If FedEx Express Lithium Battery Part 1 label (A45)is used:4a. □Shipper must be on the FedEx Express Part 1 (A45)Preapproval list. [FX-10] AND4b. □ A correctly completed IATA Lithium Battery Label must be on the package. [7.4.8]5. □Hazardous waste is prohibited. [USG-04; FX-05]6. □UN 1001, UN 1162, UN 1308 (packing group I), and UN 1873are prohibited. [FX-15]7. □Special Provision A2 (column M) prohibited even with competentauthority approval. [FX-16]The following must be on the Declaration and package:(Refer to IATA DGR 8.1.6.9.1 for allowed sequence on Declaration only.) 8a. □UN or ID number, preceded by the prefix “UN” or “ID”, is on the Declaration. [8.1.6.9.1, Step 1]8b. □UN or ID number, preceded by the prefix “UN” or “ID”, is marked on the package. [7.1.5.1 (a)]9a. □Proper shipping name (for ★ entries, the technical name in parentheses, or the word “SAMPLE”) is on the Declaration.For UN 2814 or UN 2900, technical name or “suspected categoryA infectious substance” in parentheses, is on the Declaration.[4.1.2.2; 8.1.6.9.1, Step 2; A140]9b. □Proper shipping name (for ★ entries, the technical name in parentheses, or the word “SAMPLE”) is marked on the package.[4.1.2.2; 7.1.5.1 (a)]10a. □Shipper and consignee name and address are on theDeclaration. May differ from that on the airbill [8.1.6.1; 8.1.6.2] 10b. □Shipper and consignee name and address are marked on the package. [7.1.5.1 (b)]11a. □“RQ”, if indicated as a package marking, must be on the Declaration. [2.9.2; USG-04]11b. □“RQ”, if indicated on the Declaration, must be marked on the package. [2.9.2; USG-04]12a. □DOT-E or DOT-SP approval number on the Declaration when shipped as a DOT exemption or special permit.12b. □DOT-E or DOT-SP approval number is marked on the package, if required.12c. □A copy of the DOT-E or DOT-SP letter must travel with the shipment, if required.13. If Special Provision A20 is shown in the Blue Pages:13a. □A statement similar to that shown in the Additional Handling block of Fig. 8.1.E must be on the Declaration. [A20]13b. □The Keep Away From Heat label must appear on the package.[A20]On the Declaration Only:Tracking number, airport/city of departure, and destination may be completed by the shipper or the Dangerous Goods Specialist. There must be at least 3 copies in English. 2 copies must have red hatchings. [FX-14]14. □Typewritten or computer generated. [FX-12]15. □Page of Pages. [8.1.6.4]16. □Passenger and Cargo Aircraft or Cargo Aircraft Onlylimitations correctly indicated. [8.1.6.5]17. □Radioactive deleted. [8.1.6.8]18. □Class or Division number(s), and when Class 1 is indicated,Compatibility Group letter must be included, matching column C.[8.1.6.9.1, Step 3]19. □Subsidiary Risk(s), if applicable, in parentheses, immediatelyfollowing class or division, matching column C. [8.1.6.9.1, Step 4] 20. □Packing group, when applicable (e.g., I, II or III), matchingcolumn E. If “SAMPLE” is used in place of the technical name,the shipper must select the most restrictive packing group for theproper shipping name. [3.11.1; 8.1.6.9.1, Step 5]21. □Number of packages and type of packaging (e.g., 1 fibreboardbox, 1 box fibreboard, or 1 4G fibreboard box).[8.1.6.9.2, Step 6 (a)]22. □Net quantity or gross weight (G) per package (in metric units)as allowed per the Packing Instruction, Special Provision, orDOT Special Permit, if applicable. [8.1.6.9.2, Step 6 ]23. □Packing Instruction number (e.g., 307 or Y419). Ensure allfurther requirements of the packing instruction have been met.[8.1.6.9.3, Step 8]24. □Name, title, place, date, and shipper’s signature. Signaturemay be typewritten for US domestic shipments, including USTerritories. [8.1.6.13; 8.1.6.14; 8.1.6.15]25. □24-hour emergency response telephone number; no beepersor pagers (not required for LTD QTY, or UN 1845, UN 2807,UN 2857, UN 2969, UN 3166, UN 3171, UN 3358, or ID 8000).[USG-12]26. □Shipper’s same signature next to amendments and alterations(changes). [8.1.2.6]27. □If UN 3268 or UN 0503, the EX number, CA number, or ProductCode on the Declaration. [USG-05]28. □If UN 1796, UN 1826, or UN 2031, Acid concentration is 40% orless and indicated. [FX-04]29a. □If UN 2315 or UN 3432, packaging used is acceptable per FX-06. 29b. □If UN 3077 or UN 3082 with a technical name of polychlorinated biphenyls (PCBs), packaging used is acceptable per FX-06. 30. □If UN 3090, shipper must be on the FedEx Express Fully-Regulated Lithium Battery Preapproval list. [FX-10]31. □“I DECLARE THAT ALL OF THE APPLICABLE AIRTRANSPORT REQUIREmENTS HAVE BEEN mET” mustappear in the additional handling information section or at theend of the certification statement. [8.1.6.12.2; 8.1.7]On the Package Only:32. □Package is in good condition, large enough, and free of leakage,odor, or external damage. FedEx branded packaging, includingFedEx brown boxes, must not be used. [5.0.1.2; 9.1.3; FX-11] 33. □Packageis permitted by the Packaging Instruction number.34. □strength rating(X, Y, or Z) corresponds with theX for PG I, II, or III; Y for PG II or III; or Z for PG III only; unless further limited by the packing instruction,Special Permit, or Special Provision. [6.0.4.2 (c)]35. □Primary hazard label, matching column D. The hazard labelmust be on same surface as the proper shipping name markingwhen package dimensions are adequate. [7.2.3.1; 7.2.3.2]On the Package Only (continued.):36. □Subsidiary risk label(s), matching column D. The subsidiaryrisk label, when required, must be adjacent (not opposite side) tothe primary hazard label. [7.2.3.2; 7.2.6.2.3]37. □If dry ice, the net weight (in metric units) written on the package.[7.1.5.1 (e)]38. □Cargo Aircraft Only label, when required, must be affixedon the same surface of the package near the primary hazardlabel(s). [7.2.4.2; 7.2.6.3]39. □If liquids in combination packages (including All Packed InOne)and overpacks, two package orientation labels (up arrows)on opposite sides (not required for Class 3 if inner receptaclesare 120 mL or less and Division 6.2 if inner receptacles are 50mL or less). [7.2.4.4]40. □Labels correctly applied, not obscured, not covering requiredmarkings; irrelevant markings, labels removed or obliterated.[7.1.1; 7.1.3.1; 7.1.3.2; 7.2.1; 7.2.4.5; 7.2.5; 7.2.6]Limited Quantity or LTD QTY:41a. □“LImITED QUANTITY” or “LTD QTY” is in the Authorization column on the Declaration when a “Y” packing instruction isused. [8.1.6.9.4, Step 9 (a)]41b. □“LImITED QUANTITY” or “LTD QTY” is marked on the package (not required for overpacks). [7.1.4.1; 7.1.5.3]41c. □Gross Weight of the completed package may not exceed30 kg (66 lb). [2.8.4.2]Explosives (Class 1):If 023 Air waybill, requires prior FedEx approval (prior KIAC booking) [FX-01].42. □Shippers of Fireworks 1.4G and Fireworks 1.4S must be on theFedEx Express Fireworks Preapproval list.43. Approval number (not required for ammunition, includingCartridges, Small Arms). [8.1.6.9.4, Step 9; USG-05]43a. □If DOT-E or DOT-SP, approval number on the Declaration, and a copy of the DOT-E or DOT-SP letter is attached, if required. OR 43b. □If CA or EX, approval number is either on the Declaration, or on the package (or both). A copy of the Approval document is notrequired.44. □Compatibility Group letter for explosives on the primary hazardlabel. [7.2.3.3 (b)]45. □Net quantity and Gross weight (G) (in metric units) are on thepackage. [7.1.5.1 (c)]46. □If Packing Instruction 101 is used, a Competent Authoritystatement similar to that shown in the packing instruction must beon the Declaration.Gases (Class 2):Labels of reduced size may be affixed to the shoulder of a cylinder. 47. □If the outer package is a compressed gas cylinder, thespecification markings must be stamped, engraved, or etched, ifapplicable. [6.4.2.1.1]48. If using Packing Instruction 202, then the following is required: 48a. □Cryogenic Liquid handling label. [7.2.4.3]48b. □The words “DO NOT DROP - HANDLE WITH CARE” on the package. [7.1.5.1 (g)]48c. □“KEEP UPRIGHT” must be at 120-degree intervals around a cylinder or on each side of a package. [7.1.5.1 (g)]48d. □Package orientation labels (Up arrows). [7.1.5.1 (g)]48e. □Instructions to be followed in the event of emergency, delay, or if the shipment is unclaimed. [7.1.5.1 (g)]49. □If UN 1072, must be packed in ATA Specification 300/Category lcontainers (unless overpacked) with required markings. [FX-13] 50a. □If UN 1057, approval must be on the Declaration. [USG-07]50b. □If UN 1057, approval must be marked on the package. [USG-07]Toxics (Division 6.1) Primary or Subsidiary Risk [FX-02; 2.9.4]:51a. □If 6.1 domestic shipments, packing group I or II (except UN 1230, Methanol),DOT-E or DOT-SP approval number on theDeclaration.51b. □If 6.1 domestic shipments, packing group I or II (except UN 1230, Methanol),DOT-E or DOT-SP approval number is on thepackage.51c. □If 6.1 domestic shipments, packing group I or II (except UN 1230, Methanol). A copy of the DOT-E or DOT-SP letter musttravel with the shipment.52. □If 6.1(except53. □If domestic or international shipments, packing group III, “PGIII” is written adjacent (not on opposite side) to the label. [FX-02] 54. □Class 2 substances with a toxic subsidiary risk label will notbe accepted for carriage. [FX-02]Infectious Substances (Division 6.2):Labels not more than 50% smaller than standard size may be used.55a. □The name and telephone number of a person responsible for the shipment on the Declaration. [8.1.6.11.4]55b. □The name and telephone number of a person responsible for56. □Package is [6.5.3.1.2]All Packed in One...57. □The dangerous goods are compatible. [5.0.2.11 (a) and (b)]58. □The words “ALL PACKED IN ONE” and packaging type on theDeclaration. [8.1.6.9.2, Step 6 (f)]59. □“Q” value is shown on the Declaration, and does not exceed1.0. The following are not included in the Q value calculation: dryice, commodities where columns H, J, and L indicate “No Limit”,commodities where columns J and L indicate gross weight perpackage, or commodities with the same UN number, packinggroup, and physical state. [5.0.2.11 (g) and (h)]60. □If the quantity limit in Columns J or L is shown as gross weight(G),the gross weight of the completed package must not exceedthe lowest applicable gross weight. [5.0.2.11(i)]Overpacks:61. □The dangerous goods are compatible. [5.0.1.5.1]62. □The words “OVERPACK USED” on the Declaration. [8.1.6.9.2,Step 7]63. □The word “OVERPACK” must be marked on the package if allmarkings and labels are not visible. [7.1.4.1]64. If Cargo Aircraft Only:64a. □ One package is contained in the overpack. OR64b. □ If more than one package is contained, they are assembled so clear visibility and easy access to them is possible. [5.0.1.5.3] OR 64c. □Shipment is Class 3, PG III without a subsidiary risk, or is a Class 6, 7, or 9. [5.0.1.5.3]ORm-D Only (49 CFR) - US Domestic Only (Includes US Territories): Tracking number, airport/city of departure and destination may be completed by the shipper or the Dangerous Goods Specialist. There must be at least 3 copies in English. 2 copies must have red hatchings. [FX-14] FedEx Service Guide requires compliance with all applicable FedEx variations.65. □Typewritten or computer generated. [FX-12]66a. □Proper shipping name is on the Declaration (Cartridges Small Arms, Cartridges Power Devices, or Consumer Commodity).[172.202 (a)]66b. □Proper shipping name is on the package (Cartridges Small Arms, Cartridges Power Devices, or Consumer Commodity).[172.301 (a)]67a. □“ORm-D” in the Class or Division column is on the Declaration.[172.202 (a)]67b. □“ORm-D-AIR” is on the package and enclosed within a rectangle. [172.316]68. □Number of packages and type of packaging (e.g., 1 box, 1drum, etc.) are on the Declaration. [172.202(a)]69. □Gross Weight (G) is on the Declaration.Limit is 66 lb/30 kg; maybe in lb or kg. [172.202 (a); 173.156]70. □Passenger and Cargo Aircraft or Cargo Aircraft Only isindicated on the Declaration. [172.203 (f)]71. □If Cargo Aircraft Only is indicated on the Declaration, a CargoAircraft Only label must be affixed to the package. [172.402(c)] 72a. □Name and address of both the shipper and consignee are on the Declaration.72b. □Name and address of either shipper or consignee on the package. [172.301 (d)]73. □Signature; may be typed. [172.204 (d)]74. □Required markings are not obscured.75. □Package is large enough, strong and free of leakage, odors, orexternal damage. [173.156; FX-11]76. □“I DECLARE THAT ALL OF THE APPLICABLE AIRTRANSPORT REQUIREmENTS HAVE BEEN mET” mustappear in the additional handling information section or at theend of the certification statement.[172.204(c)]Comments: _____________________________________ ______________________________________________ ______________________________________________ ______________________________________________ ______________________________________________ ______________________________________________ ______________________________________________ ______________________________________________Check here □ if 023 shipment (ATA, IP1, IXF) with no errors.When 023 shipment with no errors, file the checklist and a copy of the Declaration in the 13-month file.For further assistance, call 1-800-Go-FedEx (1-800-463-3339), then press 81 to be connected to the Dangerous Goods/Hazardous Materials Hotline.A customer job aid for IATA shipments is available at:/us/services/pdf/DG_Job_Aid_2009.pdfDISTRIBUTION: White copy - Return to ShipperYellow copy - Retain three days at origin, then discard EFFECTIVE: 01/01/09 © 2009 FedEx Express FedEx M-2140 01/09 LOGOS 139203 WCS All rights reserved.。

PreSonus 产品安全警告和说明书

PreSonus Safety Warnings and InstructionsElectrical information and warning symbols for PreSonus products are located on the rear electrical panel of the unit adjacent to the electrical plug or on the bottom of the unit along with other product compliance information.This lightning flash with arrowhead symbol within an equilateral triangle is intended to alert the user to the presence of non-insulated “dangerous voltage” within the product’s enclosure that may be of sufficient magnitude to constitute a risk of electric shock.WARNING: TO REDUCE THE RISK OF ELECTRIC SHOCK, DO NOT REMOVE COVER (OR BACK) AS THERE ARE NO USER-SERVICEABLE PARTS INSIDE. REFER SERVICING TO QUALIFIED PERSONNEL. The exclamation point within an equilateral triangle is intended to alert the user to the presence of important operating and maintenance instructions in the literature accompanying the appliance.CAUTION: To reduce the risk of electric shock, do not expose this appliance to rain and moisture. Do not expose this device to dripping or splashing liquids and no object filled with liquids, such as vases, should be placed on the device.CAUTION: These service instructions are for use by qualified service personnel only. To reduce the risk of electric shock, do not perform any servicing other than that contained in the operation instructions. Qualified service personnel must perform repairs.1.Read these instructions.2.Keep these instructions.3.Heed all warnings.4.Follow all instructions.5.Do not use this device near water.6.Clean only with a dry cloth.7.Do not block any ventilation openings. Install in accordance with the manufacturer’s instructions.8.Do not install near any heat sources, such as radiators, heat registers, stoves, or other device (including amplifiers) that produce heat.9.Do not defeat the safety purpose of the polarized or grounding-type plug. A polarized plug has two blades and a third grounding prong. The wide blade and the third prong are provided for your safety. If the provided plug does not fit into your outlet, consult an electrician for replacement of the obsolete outlet. 10.Protect the power cord from being walked on or pinched, particularly at plugs, convenience receptacles, and the point where they exit from the device. e only attachments/accessories specified by PreSonus.e only with a cart, stand, tripod, bracket, or table specified by the manufacturer or sold with this device. Use caution when moving a cart/device combination to avoid injury from tip-over.13.Unplug this device during lightning storms or when unused for long periods.14.Servicing is required when the device has been damaged in any way, such as if a power-supply cord or plug is damaged; or liquid is spilled, or objects have fallen into the device; or if the device has been exposed to rain or moisture, does not operate normally, or has been dropped. All PreSonus products in the USA should be serviced at the PreSonus factory in Baton Rouge, Louisiana. If your PreSonus product requires a repair, contact support@ to arrange for a return authorization number. Customers outside the USAshould contact their local distributor. Your distributor’s contact information is available at .15.Protective grounding(earthing) terminal. The apparatus should be connected to a mains socket outlet with a protective grounding(earthing) connection.16.Where the Mains plug or an appliance coupler is used as the disconnect device, the disconnect device shall remain readily operable. 17.The use of apparatus is in moderate climates.18.Please allow 5cm around the apparatus for sufficient ventilation; the ventilation should not be impeded by covering the ventilation openings with items, such as newspapers, table-cloths, curtains, etc.Rackmounting•Use an equipment rack that is 19-inches wide (482.6 mm) and rated for the total weight of your equipment.•Use a minimum of (4) 10/32 threaded screws per rack mounted device.WARNING:Cancer and reproductive harm - PreSonus Compliance Information European Union (EU)The CE mark on this product indicates that the device is compliant with the EU Council Directives2014/35/EU Low Voltage Directive 2014/30/EU EMC Directive 2011/65/EU RoHS Recast EC 1907/2006 REAChFor a copy of a specific product DoC, contact PreSonus at support@.RoHS Recast Directive 2011/65/EU REACh Directive EC1907/206WEEE This symbol on this product or its packaging indicates that this product must not be disposed of with other waste. Instead, it is your responsibility to dispose of your waste equipment by handing it over to a designated collection point for the recycling of waste electrical and electronic equipment. The separate collection and recycling of your waste equipment at the time of disposal will help conserve natural resources and ensure that it is recycled in a manner that protects human health and the environment. For more information about where you can drop off your waste equipment for recycling, please contact your local city recycling office or the dealer from whom you purchased the product.Radio and Television InterferenceIf these symbols are marked on the product, the device complies as follows:Any Changes or modifications not expressly approved by the party responsible for compliance could void the user’s authority to operate the equipment.USA: This equipment has been tested and found to comply with the limits for a Class B digital device, pursuant to Part 15 of the FCC Rules. Operation is subject to the following two conditions: (1) This device may not cause harmful interference, and (2) this device must accept any interference received, including interference that may cause undesired operation. These limits are designed to provide reasonable protection against harmful interference in a residential installation. This equipment generates, uses, and can radiate radio frequency energy, and, if not installedin accordance with the instructions, may cause harmful interference to radio communications. However, there is no guarantee that interference will not occur in a particular installation. If this equipment does cause harmful interference to radio or television reception, which can be determined by turning the equipment off and on, the user is encouraged to try to correct the interference by one or more of the following measures:•Reorient or relocate the receiving antenna.•Increase the separation between the equipment and the receiver.•Connect the equipment into an outlet on a circuit different from that to which the receiver is connected.•Consult the dealer or an experienced radio/TV technician for help.FCC Radiation Exposure Statement:This equipment complies with FCC radiation exposure limits set forth for an uncontrolled environment. This equipment should be installed and operated with minimum distance 20cm between the radiator& your body.This transmitter must not be co-located or operating in conjunction with any other antenna or transmitter.CAUTION: Changes or modifications to this device not expressly approved by PreSonus Audio Electronics could void the user’s authority to operate the equipment under FCC rules.Australian Compliance: This equipment complies with Radio communication Devices Notice 2003; or Radio communication Labeling (Electromagnetic Compatibility) Notice 2008; or Radio communication (Compliance Labeling Electromagnetic Radiation) Labeling Notice 2003.IC WARNINGIC RSS warning: This device complies with Industry Canada licence-exempt RSS standard (s). Operation is subject to the following two conditions: (1) this device may not cause interference, and (2) this device must accept any interference,including interference that may cause undesired operation of the device. Under Industry Canada regulations, this radio transmitter may only operate using an antenna of a type and maximum (or lesser) gain approved for the transmitter by Industry Canada. To reduce potential radio interference to other users, the antenna type and its gain should be so chosen that, the equivalent isotropically radiated power (e.i.r.p.) is not more than that necessary for successful communication.This radio transmitter (identify the device by certifcation number, or model number if Category II) has been approved by Industry Canada to operate with the antenna types listed below with the maximum permissible gain and required antenna impedance for each antenna type indicated. Antenna types not included in this list, having a gain greater than the maximum gain indicated for that type, are strictly prohibited for use with this device.IC Radiation Exposure Statement:This equipment complies with IC RF radiation exposure limits set forth for an uncontrolled environment. This transmitter must not be co-located or operating in conjunction with any other antenna or transmitter.ICES003: This CAN ICES3 (B)/NMB3(B) digital apparatus complies with Canadian ICES003.PreSonus Health, Safety, and Compliance GuideClass BPreSonus Health, Safety, and Compliance GuideClass B®PreSonus Health, Safety, and Compliance Guide. Part# 70-00000013-C © 2018 PreSonus Audio Electronics, Inc. All Rights Reserved.18011 Grand Bay Ct. • Baton Rouge, Louisiana 70809 USA • 1-225-216-7887 Avisos e instrucciones de seguridad de PreSonusLos símbolos de información eléctrica y avisos para los productos PreSonus se encuentran en el panel posterior eléctrico de la unidad junto al enchufe eléctrico o en la parte inferior de la unidad junto con otra información de conformidad del producto.Este símbolo de un relámpago con una punta de flecha, dentro de un triángulo equilátero, es paraadvertir al usuario de la presencia de ‘voltaje peligroso’ sin aislamiento dentro del aparato que puedeser de la suficiente magnitud como para constituir un riesgo de descarga eléctrica.AVISO: PARA REDUCIR EL RIESGO DE DESCARGA ELÉCTRICA, NO QUITE LA CUBIERTA (O LAPARTE POSTERIOR) YA QUE NO HAY PIEZAS QUE EL USUARIO PUEDA REPARAR EN EL INTERIOR.REMITA TODO SERVICIO DE MANTENIMIENTO A PERSONAL TÉCNICO CUALIFICADO.El signo de exclamación dentro de un triángulo equilátero avisa al usuario de que existen instruccionesde operación y mantenimiento importantes en la documentación que acompaña al dispositivo.PRECAUCIÓN: Para reducir el riesgo de descarga eléctrica, no exponga este equipo a la lluvia o humedad. No exponga este dispositivo al goteo ni salpicadura de líquidos y ningún objeto lleno de algún líquido, como jarrones, deberíacolocarse sobre el dispositivo.PRECAUCIÓN: Estas instrucciones de servicio son para el uso sólo de personal de mantenimiento cualificado. Parareducir el riesgo de descarga eléctrica, no realice ningún mantenimiento más que el indicado en las instrucciones demanejo. Sólo el personal de mantenimiento cualificado debe realizar las reparaciones.1.Lea estas instrucciones.2.Guarde estas instrucciones.3.Haga caso a todos los avisos.4.Siga todas las instrucciones.5.No use este dispositivo cerca del agua.6.Límpielo sólo con un trapo suave y seco.7.No bloquee ninguna apertura de ventilación. Instale este aparato de acuerdo con las instrucciones del fabricante.8.No instale esta unidad cerca de fuentes de calor como radiadores, calentadores, hornosu otros dispositivos (incluyendo amplificadores) que produzcan calor.9.No anule el sistema de seguridad que supone un enchufe polarizado o uno con toma de tierra. Uno polarizado tiene dospatas planas y una tercera pata redonda de toma de tierra. La pata más ancha y la tercera pata se incluyen para su seguridad.Si el enchufe suministrado no encaja en su toma corriente, consulte a un electricista para sustituir la toma obsoleta.10.Evite que el cable de corriente pueda quedar aplastado, retorcido o ser pisado, especialmenteen los enchufes, receptáculos y en el punto en donde salen del dispositivo.e sólo los montajes/accesorios especificados por PreSonus.12.Utilice esta unidad solo con un bastidor, soporte, trípode, mesa o base especificado porel fabricante o que se venda junto con este dispositivo. Tenga cuidado al mover unacombinación de carrito/dispositivo para evitar lesiones producidas por vuelcos.13.Desenchufe este dispositivo de la corriente durante tormentas eléctricaso cuando no se use durante largos periodos de tiempo.14.Es necesario realizar un mantenimiento del dispositivo cuando haya sufrido algúntipo de daño, como cuando se haya dañado el enchufe o cable de alimentación,se haya derramado líquido o se hayan introducido objetos en el dispositivo, o si eldispositivo haya sido expuesto a lluvia o humedad, no funcione de manera normalo se le haya caído. Todos los productos PreSonus en los USA deben recibir mantenimiento en la fábrica de PreSonusen Baton Rouge, Louisiana. Si su producto PreSonus requiere una reparación, contacte con support@presonus.com para conseguir un número de autorización de devolución. Los clientes fuera de los USA deberían contactar consu distribuidor local. La información de contacto de su distribuidor está disponible en 15.Terminal con protección de toma de tierra. El aparato debería de conectarse a unenchufe de corriente con una conexión de protección de toma de tierra.16.Donde el enchufe Mains o un dispositivo acoplador se use como dispositivo dedesconexión, el dispositivo de desconexión debería ser sencillo de manejar.17.El uso del aparato es en climas moderados.18.Por favor deje libres unos 5cm alrededor del aparato para una ventilación suficiente; la ventilación no deberíaverse obstruida cubriendo las aperturas de ventilación con artículos como periódicos, manteles, cortinas, etc. Montaje en rack•Use un bastidor de rack de 19 pulgadas de ancho (482.6 mm) y calibrado para el peso total de su equipo.•Use un mínimo de (4) tornillos de rosca de 10/32 por dispositivo montado en rack.AVISO:Cáncer y daños en el sistema reproductor - Información sobre cumplimiento de PreSonusUnión Europea (UE)La marca CE en este producto indica que el dispositivo es de conformidad con lasDirectivas del Consejo de la UE.2014/35/EU Directiva sobre bajo voltaje2014/30/EU Directiva EMC2011/65/EU RoHS RecastEC 1907/2006 REAChPara conseguir una copia DoC de un producto específico, contacte con PreSonus en support@.RoHS Recast Directiva 2011/65/EUREACh Directiva EC1907/206WEEE Este símbolo en este producto o en su embalaje indica que este producto no debe echarse a la basura con otros desperdicios. En vez de eso, es su responsabilidad deshacerse de los residuos de su equipo entregándolo en un puntode recolección designado para el reciclaje de residuos de equipos eléctricos o electrónicos. La recolección aparte yreciclaje de los restos de su equipo cuando vaya a deshacerse de él, ayudará a conservar los recursos naturales y agarantizar que está reciclado de forma que proteja la salud humana y del entorno. Para más información sobre dondepuede echar los residuos de su equipo para su reciclaje, por favor contacte con la oficina de reciclaje de su ciudad ocon el distribuidor al que le compró el producto.Interferencias con la radio y la televisiónSi estos símbolos están marcados en el producto, el dispositivo cumple lo siguiente:Cualquier cambio o modificación que no haya sido expresamente aprobado por la parte responsable de la conformidad normativa puede invalidar la autoridad del usuario para manejar este equipo.USA: Este equipo ha sido probado y se ha visto que cumple con la normativa para dispositivos digitales Class B, deacuerdo con la Parte 15 de la Normativa FCC. Su manejo está sujeto a las siguientes dos condiciones: (1) estedispositivo no debe causar interferencias dañinas, y (2) este dispositivo debe aceptar cualquier interferenciarecibida, incluyendo las interferencias que puedan causar un funcionamiento no deseado. Estos límites han sidodiseñados para ofrecer una razonable protección contra interferencias dañinas en una instalación residencial. Este equipo genera, usa, y es capaz de emitir frecuencias de radio y, si no se instala siguiendo las instrucciones, puede causar interferenciasdañinas a las comunicaciones por radio. No obstante, no hay ninguna garantía de que no se producirá alguna interferencia en una instalación en particular. Si este equipo causara interferencias dañinas sobre la recepción de frecuenias de radio o televisión, que puede determinarse apagando y encendiendo el equipo, se anima al usuario a que intente corregir la interferencia siguiendo una o varias de las siguientes medidas:•Reoriente o coloque la antena receptora en otro lugar.•Aumente la separación entre el equipo y el receptor.•Conecte el equipo a una toma en un circuito distinto al que el receptor esté conectado.•Consulte al vendedor o a un técnico experimentado en radio/TV para más ayuda.Declaración FCC de exposición a radiación:Este equipo cumple con los límites FCC de exposición a la radiación expuestos para un entorno no controlado. Este equipo debería instalarse y manejarse con una distancia mínima de 20 cm entre el radiador y su cuerpo.Este transmisor no debe colocarse ni funcionar junto con cualquier otra antena o transmisor.PRECAUCIÓN: Los cambios o modificaciones realizados sobre este dispositivo sin la aprobación expresa de PreSonus Audio Electronics podrían invalidar la autoridad del usuario de utilizar el equipo bajo las normas FCC.Cumplimiento de las normas australianas: Este equipo cumple con la Radio communication Devices Notice 2003; ó Radio communication Labeling (Electromagnetic Compatibility) Notice 2008; ó Radio communication (Compliance LabelingElectromagnetic Radiation) Labeling Notice 2003.AVISO IC:Aviso IC RSS: Este dispositivo cumple con los estándares RSS de no exigencia de licencia de Industry Canada. Su manejo está sujeto a las siguientes dos condiciones: (1) este dispositivo no debe causar interferencias, y (2) este dispositivo debe aceptar cualquier interferencia, incluyendo las interferencias que puedan causar un funcionamiento no deseado del dispositivo. Bajo la normativa de Industry Canada, este radio transmisor solo puede funcionar usando una antena de un tipo y de una ganancia máxima (o menor) aprobada para el transmisor por Industry Canada. Para reducir las potenciales interferencias de radio a otros usuarios, el tipo de antena y su ganancia debaerían elegirse de forma que, la corriente equivalente radiada de forma isotrópica (e.i.r.p.) no sea más que la necesaria para una buena comunicación.Este radio transmisor (identificar el dispositivo por el número de certificación, o número de modelo si es de la Categoría II) ha sido aprobado por Industry Canada para funcionar con los tipos de antena que aparecen en la lista de abajo con la máxima ganancia permitida e impedancia de antena requerida para cada tipo de antena indicado. Los tipos de antena no incluidos en esta lista, teniendo una ganancia mayor que la ganancia máxima indicada para ese tipo, están estrictamente prohibidos para su uso con este dispositivo.Declaración de exposición a radiación IC:Este equipo cumple con los límites IC RF de exposición a la radiación expuestos para un entorno no controlado. Este transmisor no debe colocarse ni funcionar junto con cualquier otra antena o transmisor.ICES003: Este CAN ICES3 (B)/NMB3(B) aparato digital cumple con la normativa canadiense ICES003.Guía de salud, seguridad y conformidad de PreSonus Class B普瑞声纳(PreSonus)安全警示与说明普瑞声纳(PreSonus)产品的电气信息和警示标志以及其它产品合规信息一并位于电源插头旁、设备后部的电气面板上，或位于设备底部。

Schmitt Trigger说明书

Application BriefUnderstanding Schmitt Triggers Most CMOS, BiCMOS and TTL devices require fastedges on the high and low transitions of their inputs. If the edges are too slow, they can cause excessive current, oscillation, or may damage the device.Slow or Noisy EdgesSlow edges are sometimes hard to avoid at power-up or when using push-button or manual switches with the large capacitors needed for filtering. Heavily loaded outputs can also cause input rise and fall time to be out of specification for the next part down the line. On a normal (non-Schmitt trigger) input, the part will switch at the same point on the rising edge and falling edge. With a slow rising edge the part will switch at the threshold. When the switch occurs, it will require current from Vcc.When current is forced from VCC, the VCC levelcan drop and cause the threshold to shift. When the threshold shifts it will cross the input again causing the part to switch again. This pattern can continue causing oscillation, which can cause excessive current. This pattern can also happen if noise is on the input. The noise can cross the threshold multiple times and cause oscillation or multiple clocking.HysteresisThe solution to these problems is to use a Schmitt trigger device to translate the slow or noisy edges into something faster that will meet the input rise and fall specifications of the following device. A true Schmitt trigger does not have rise and fall time limitations. Parts with Schmitt trigger action have a small amount of hysteresis that helps with noise rejection butstill have an input rise and fall time-limit. Theseparts usually do not have VT specifications in the data sheet and have rise and fall time limitations specified for the inputs in the recommended operating conditions.The true Schmitt trigger input has the switching threshold adjusted where the part will switch at a higher point (Vt+) on the rising edge and at a lower point (Vt–) on the falling edge. The difference in these switching points is called Hysteresis (^Vt). Here is an example of Schmitt trigger specs:SCEA046A – SEPTEMBER 2011 – REVISED NOVEMBER 2022Submit Document FeedbackUnderstanding Schmitt Triggers1It is important to remember (Vt+ max) = Vih and (VT–min) = Vil. In the specs, multiple limits are relatedto the Schmitt trigger inputs. All of the limits areimportant for different reasons. On the input risingedge, the part will switch between (Vt+ min) and (Vt+max). On the falling edge, the part will switch between(Vt– max) and (Vt– min). The part will not switchbetween (Vt– max) and (Vt+ min). This is importantfor noise rejection.The hysteresis is the delta between where the partswitches on the rising edge and where it switches onthe falling edge. The hysteresis will be at least the minand no more than the max (^Vt) spec.Figure 1.In the figure above, the input levels Vih and Vil mustbe greater than (VT+ max) and less than (VT– min)to ensure the part will switch. The switching points onthe above plot are separated to give a clearer visualpicture. In reality, the (VT+ min) and (VT– max) mayoverlap.Input VoltageOne common misconception is that the currentconsumption will be less when switching a slow signalinto a Schmitt trigger. This misconception is partly truebecause the Schmitt trigger prevents oscillation whichcan draw a lot of current; however, the Icc currentmay still be higher due to the amount of time the inputis not at the rail. This is Delta Icc. Delta Icc is wherethe inputs are not at the rails and upper or lower drivetransistors are partially on. The plot below shows Iccacross the input voltage sweep.Figure 2. Supply Current as a Function of InputVoltageSine WavesUse Schmitt triggers to translate a sine wave into asquare wave as shown in this oscillator application.Also, use Schmitt triggers to speed up a slow ornoisy input, or clean up an input, as in the switchde-bouncer circuit.2Understanding Schmitt Triggers SCEA046A – SEPTEMBER 2011 – REVISED NOVEMBER 2022Submit Document FeedbackFigure 3. Oscillator Application Using SchmittTrigger InverterFigure 4. Switch De-bouncer Using SchmittTrigger InverterConclusionSchmitt triggers can be used to change a sine wave into a square wave, clean up noisy signals, andconvert slow edges to fast edges.Figure 5. Sine Wave to Square WaveFigure 6. Clean Noisy SignalsFigure 7. Convert Slow EdgesWe specify the part will switch on the rising edge between (VT+ min) and (VT+ max). We specify the part will switch on the falling edge between (VT– max) and (VT– min).Between (VT+ min) and (VT– max), we specify the part will not switch. This specification can be used for noise rejection. These 2 limits can overlap.We specify a minimum amount of hysteresis as delta VT min.•Vih = (VT+ max)•Vil = (VT– min)Texas Instrument Schmitt trigger functions areavailable in most all technology families from the 30 year old 74XX family to the latest AUP1T family. These two Schmitt-trigger functions are available in most families:•14 for inverting Schmitt trigger•17 for non-inverting Schmitt triggerTexas Instrument also has a complete line of little logic products with Schmitt trigger inputs.ConfigurationsSN74LVC1G57, SN74LVC1G58, SN74LVC1G97, SN74LVC1G98, SN74LVC1G99 SN74AUP1G57, SN74AUP1G58, SN74AUP1G97, SN74AUP1G98, SN74AUP1G99Low to High TranslatorsSN74AUP1T02, SN74AUP1T04, SN74AUP1T08, SN74AUP1T14, SN74AUP1T157, SN74AUP1T158, SN74AUP1T17, SN74AUP1T32, SN74AUP1T86SCEA046A – SEPTEMBER 2011 – REVISED NOVEMBER 2022Submit Document FeedbackUnderstanding Schmitt Triggers 3IMPORTANT NOTICE AND DISCLAIMERTI PROVIDES TECHNICAL AND RELIABILITY DATA (INCLUDING DATA SHEETS), DESIGN RESOURCES (INCLUDING REFERENCE DESIGNS), APPLICATION OR OTHER DESIGN ADVICE, WEB TOOLS, SAFETY INFORMATION, AND OTHER RESOURCES “AS IS” AND WITH ALL FAULTS, AND DISCLAIMS ALL WARRANTIES, EXPRESS AND IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS.These resources are intended for skilled developers designing with TI products. You are solely responsible for (1) selecting the appropriate TI products for your application, (2) designing, validating and testing your application, and (3) ensuring your application meets applicable standards, and any other safety, security, regulatory or other requirements.These resources are subject to change without notice. TI grants you permission to use these resources only for development of an application that uses the TI products described in the resource. Other reproduction and display of these resources is prohibited. No license is granted to any other TI intellectual property right or to any third party intellectual property right. TI disclaims responsibility for, and you will fully indemnify TI and its representatives against, any claims, damages, costs, losses, and liabilities arising out of your use of these resources.TI’s products are provided subject to TI’s Terms of Sale or other applicable terms available either on or provided in conjunction with such TI products. TI’s provision of these resources does not expand or otherwise alter TI’s applicable warranties or warranty disclaimers for TI products.TI objects to and rejects any additional or different terms you may have proposed.Mailing Address: Texas Instruments, Post Office Box 655303, Dallas, Texas 75265Copyright © 2022, Texas Instruments Incorporated。

OSHA现场作业手册说明书

DIRECTIVE NUMBER: CPL 02-00-150 EFFECTIVE DATE: April 22, 2011 SUBJECT: Field Operations Manual (FOM)ABSTRACTPurpose: This instruction cancels and replaces OSHA Instruction CPL 02-00-148,Field Operations Manual (FOM), issued November 9, 2009, whichreplaced the September 26, 1994 Instruction that implemented the FieldInspection Reference Manual (FIRM). The FOM is a revision of OSHA’senforcement policies and procedures manual that provides the field officesa reference document for identifying the responsibilities associated withthe majority of their inspection duties. This Instruction also cancels OSHAInstruction FAP 01-00-003 Federal Agency Safety and Health Programs,May 17, 1996 and Chapter 13 of OSHA Instruction CPL 02-00-045,Revised Field Operations Manual, June 15, 1989.Scope: OSHA-wide.References: Title 29 Code of Federal Regulations §1903.6, Advance Notice ofInspections; 29 Code of Federal Regulations §1903.14, Policy RegardingEmployee Rescue Activities; 29 Code of Federal Regulations §1903.19,Abatement Verification; 29 Code of Federal Regulations §1904.39,Reporting Fatalities and Multiple Hospitalizations to OSHA; and Housingfor Agricultural Workers: Final Rule, Federal Register, March 4, 1980 (45FR 14180).Cancellations: OSHA Instruction CPL 02-00-148, Field Operations Manual, November9, 2009.OSHA Instruction FAP 01-00-003, Federal Agency Safety and HealthPrograms, May 17, 1996.Chapter 13 of OSHA Instruction CPL 02-00-045, Revised FieldOperations Manual, June 15, 1989.State Impact: Notice of Intent and Adoption required. See paragraph VI.Action Offices: National, Regional, and Area OfficesOriginating Office: Directorate of Enforcement Programs Contact: Directorate of Enforcement ProgramsOffice of General Industry Enforcement200 Constitution Avenue, NW, N3 119Washington, DC 20210202-693-1850By and Under the Authority ofDavid Michaels, PhD, MPHAssistant SecretaryExecutive SummaryThis instruction cancels and replaces OSHA Instruction CPL 02-00-148, Field Operations Manual (FOM), issued November 9, 2009. The one remaining part of the prior Field Operations Manual, the chapter on Disclosure, will be added at a later date. This Instruction also cancels OSHA Instruction FAP 01-00-003 Federal Agency Safety and Health Programs, May 17, 1996 and Chapter 13 of OSHA Instruction CPL 02-00-045, Revised Field Operations Manual, June 15, 1989. This Instruction constitutes OSHA’s general enforcement policies and procedures manual for use by the field offices in conducting inspections, issuing citations and proposing penalties.Significant Changes∙A new Table of Contents for the entire FOM is added.∙ A new References section for the entire FOM is added∙ A new Cancellations section for the entire FOM is added.∙Adds a Maritime Industry Sector to Section III of Chapter 10, Industry Sectors.∙Revises sections referring to the Enhanced Enforcement Program (EEP) replacing the information with the Severe Violator Enforcement Program (SVEP).∙Adds Chapter 13, Federal Agency Field Activities.∙Cancels OSHA Instruction FAP 01-00-003, Federal Agency Safety and Health Programs, May 17, 1996.DisclaimerThis manual is intended to provide instruction regarding some of the internal operations of the Occupational Safety and Health Administration (OSHA), and is solely for the benefit of the Government. No duties, rights, or benefits, substantive or procedural, are created or implied by this manual. The contents of this manual are not enforceable by any person or entity against the Department of Labor or the United States. Statements which reflect current Occupational Safety and Health Review Commission or court precedents do not necessarily indicate acquiescence with those precedents.Table of ContentsCHAPTER 1INTRODUCTIONI.PURPOSE. ........................................................................................................... 1-1 II.SCOPE. ................................................................................................................ 1-1 III.REFERENCES .................................................................................................... 1-1 IV.CANCELLATIONS............................................................................................. 1-8 V. ACTION INFORMATION ................................................................................. 1-8A.R ESPONSIBLE O FFICE.......................................................................................................................................... 1-8B.A CTION O FFICES. .................................................................................................................... 1-8C. I NFORMATION O FFICES............................................................................................................ 1-8 VI. STATE IMPACT. ................................................................................................ 1-8 VII.SIGNIFICANT CHANGES. ............................................................................... 1-9 VIII.BACKGROUND. ................................................................................................. 1-9 IX. DEFINITIONS AND TERMINOLOGY. ........................................................ 1-10A.T HE A CT................................................................................................................................................................. 1-10B. C OMPLIANCE S AFETY AND H EALTH O FFICER (CSHO). ...........................................................1-10B.H E/S HE AND H IS/H ERS ..................................................................................................................................... 1-10C.P ROFESSIONAL J UDGMENT............................................................................................................................... 1-10E. W ORKPLACE AND W ORKSITE ......................................................................................................................... 1-10CHAPTER 2PROGRAM PLANNINGI.INTRODUCTION ............................................................................................... 2-1 II.AREA OFFICE RESPONSIBILITIES. .............................................................. 2-1A.P ROVIDING A SSISTANCE TO S MALL E MPLOYERS. ...................................................................................... 2-1B.A REA O FFICE O UTREACH P ROGRAM. ............................................................................................................. 2-1C. R ESPONDING TO R EQUESTS FOR A SSISTANCE. ............................................................................................ 2-2 III. OSHA COOPERATIVE PROGRAMS OVERVIEW. ...................................... 2-2A.V OLUNTARY P ROTECTION P ROGRAM (VPP). ........................................................................... 2-2B.O NSITE C ONSULTATION P ROGRAM. ................................................................................................................ 2-2C.S TRATEGIC P ARTNERSHIPS................................................................................................................................. 2-3D.A LLIANCE P ROGRAM ........................................................................................................................................... 2-3 IV. ENFORCEMENT PROGRAM SCHEDULING. ................................................ 2-4A.G ENERAL ................................................................................................................................................................. 2-4B.I NSPECTION P RIORITY C RITERIA. ..................................................................................................................... 2-4C.E FFECT OF C ONTEST ............................................................................................................................................ 2-5D.E NFORCEMENT E XEMPTIONS AND L IMITATIONS. ....................................................................................... 2-6E.P REEMPTION BY A NOTHER F EDERAL A GENCY ........................................................................................... 2-6F.U NITED S TATES P OSTAL S ERVICE. .................................................................................................................. 2-7G.H OME-B ASED W ORKSITES. ................................................................................................................................ 2-8H.I NSPECTION/I NVESTIGATION T YPES. ............................................................................................................... 2-8 V.UNPROGRAMMED ACTIVITY – HAZARD EVALUATION AND INSPECTION SCHEDULING ............................................................................ 2-9 VI.PROGRAMMED INSPECTIONS. ................................................................... 2-10A.S ITE-S PECIFIC T ARGETING (SST) P ROGRAM. ............................................................................................. 2-10B.S CHEDULING FOR C ONSTRUCTION I NSPECTIONS. ..................................................................................... 2-10C.S CHEDULING FOR M ARITIME I NSPECTIONS. ............................................................................. 2-11D.S PECIAL E MPHASIS P ROGRAMS (SEP S). ................................................................................... 2-12E.N ATIONAL E MPHASIS P ROGRAMS (NEP S) ............................................................................... 2-13F.L OCAL E MPHASIS P ROGRAMS (LEP S) AND R EGIONAL E MPHASIS P ROGRAMS (REP S) ............ 2-13G.O THER S PECIAL P ROGRAMS. ............................................................................................................................ 2-13H.I NSPECTION S CHEDULING AND I NTERFACE WITH C OOPERATIVE P ROGRAM P ARTICIPANTS ....... 2-13CHAPTER 3INSPECTION PROCEDURESI.INSPECTION PREPARATION. .......................................................................... 3-1 II.INSPECTION PLANNING. .................................................................................. 3-1A.R EVIEW OF I NSPECTION H ISTORY .................................................................................................................... 3-1B.R EVIEW OF C OOPERATIVE P ROGRAM P ARTICIPATION .............................................................................. 3-1C.OSHA D ATA I NITIATIVE (ODI) D ATA R EVIEW .......................................................................................... 3-2D.S AFETY AND H EALTH I SSUES R ELATING TO CSHO S.................................................................. 3-2E.A DVANCE N OTICE. ................................................................................................................................................ 3-3F.P RE-I NSPECTION C OMPULSORY P ROCESS ...................................................................................................... 3-5G.P ERSONAL S ECURITY C LEARANCE. ................................................................................................................. 3-5H.E XPERT A SSISTANCE. ........................................................................................................................................... 3-5 III. INSPECTION SCOPE. ......................................................................................... 3-6A.C OMPREHENSIVE ................................................................................................................................................... 3-6B.P ARTIAL. ................................................................................................................................................................... 3-6 IV. CONDUCT OF INSPECTION .............................................................................. 3-6A.T IME OF I NSPECTION............................................................................................................................................. 3-6B.P RESENTING C REDENTIALS. ............................................................................................................................... 3-6C.R EFUSAL TO P ERMIT I NSPECTION AND I NTERFERENCE ............................................................................. 3-7D.E MPLOYEE P ARTICIPATION. ............................................................................................................................... 3-9E.R ELEASE FOR E NTRY ............................................................................................................................................ 3-9F.B ANKRUPT OR O UT OF B USINESS. .................................................................................................................... 3-9G.E MPLOYEE R ESPONSIBILITIES. ................................................................................................. 3-10H.S TRIKE OR L ABOR D ISPUTE ............................................................................................................................. 3-10I. V ARIANCES. .......................................................................................................................................................... 3-11 V. OPENING CONFERENCE. ................................................................................ 3-11A.G ENERAL ................................................................................................................................................................ 3-11B.R EVIEW OF A PPROPRIATION A CT E XEMPTIONS AND L IMITATION. ..................................................... 3-13C.R EVIEW S CREENING FOR P ROCESS S AFETY M ANAGEMENT (PSM) C OVERAGE............................. 3-13D.R EVIEW OF V OLUNTARY C OMPLIANCE P ROGRAMS. ................................................................................ 3-14E.D ISRUPTIVE C ONDUCT. ...................................................................................................................................... 3-15F.C LASSIFIED A REAS ............................................................................................................................................. 3-16VI. REVIEW OF RECORDS. ................................................................................... 3-16A.I NJURY AND I LLNESS R ECORDS...................................................................................................................... 3-16B.R ECORDING C RITERIA. ...................................................................................................................................... 3-18C. R ECORDKEEPING D EFICIENCIES. .................................................................................................................. 3-18 VII. WALKAROUND INSPECTION. ....................................................................... 3-19A.W ALKAROUND R EPRESENTATIVES ............................................................................................................... 3-19B.E VALUATION OF S AFETY AND H EALTH M ANAGEMENT S YSTEM. ....................................................... 3-20C.R ECORD A LL F ACTS P ERTINENT TO A V IOLATION. ................................................................................. 3-20D.T ESTIFYING IN H EARINGS ................................................................................................................................ 3-21E.T RADE S ECRETS. ................................................................................................................................................. 3-21F.C OLLECTING S AMPLES. ..................................................................................................................................... 3-22G.P HOTOGRAPHS AND V IDEOTAPES.................................................................................................................. 3-22H.V IOLATIONS OF O THER L AWS. ....................................................................................................................... 3-23I.I NTERVIEWS OF N ON-M ANAGERIAL E MPLOYEES .................................................................................... 3-23J.M ULTI-E MPLOYER W ORKSITES ..................................................................................................................... 3-27 K.A DMINISTRATIVE S UBPOENA.......................................................................................................................... 3-27 L.E MPLOYER A BATEMENT A SSISTANCE. ........................................................................................................ 3-27 VIII. CLOSING CONFERENCE. .............................................................................. 3-28A.P ARTICIPANTS. ..................................................................................................................................................... 3-28B.D ISCUSSION I TEMS. ............................................................................................................................................ 3-28C.A DVICE TO A TTENDEES .................................................................................................................................... 3-29D.P ENALTIES............................................................................................................................................................. 3-30E.F EASIBLE A DMINISTRATIVE, W ORK P RACTICE AND E NGINEERING C ONTROLS. ............................ 3-30F.R EDUCING E MPLOYEE E XPOSURE. ................................................................................................................ 3-32G.A BATEMENT V ERIFICATION. ........................................................................................................................... 3-32H.E MPLOYEE D ISCRIMINATION .......................................................................................................................... 3-33 IX. SPECIAL INSPECTION PROCEDURES. ...................................................... 3-33A.F OLLOW-UP AND M ONITORING I NSPECTIONS............................................................................................ 3-33B.C ONSTRUCTION I NSPECTIONS ......................................................................................................................... 3-34C. F EDERAL A GENCY I NSPECTIONS. ................................................................................................................. 3-35CHAPTER 4VIOLATIONSI. BASIS OF VIOLATIONS ..................................................................................... 4-1A.S TANDARDS AND R EGULATIONS. .................................................................................................................... 4-1B.E MPLOYEE E XPOSURE. ........................................................................................................................................ 4-3C.R EGULATORY R EQUIREMENTS. ........................................................................................................................ 4-6D.H AZARD C OMMUNICATION. .............................................................................................................................. 4-6E. E MPLOYER/E MPLOYEE R ESPONSIBILITIES ................................................................................................... 4-6 II. SERIOUS VIOLATIONS. .................................................................................... 4-8A.S ECTION 17(K). ......................................................................................................................... 4-8B.E STABLISHING S ERIOUS V IOLATIONS ............................................................................................................ 4-8C. F OUR S TEPS TO BE D OCUMENTED. ................................................................................................................... 4-8 III. GENERAL DUTY REQUIREMENTS ............................................................. 4-14A.E VALUATION OF G ENERAL D UTY R EQUIREMENTS ................................................................................. 4-14B.E LEMENTS OF A G ENERAL D UTY R EQUIREMENT V IOLATION.............................................................. 4-14C. U SE OF THE G ENERAL D UTY C LAUSE ........................................................................................................ 4-23D.L IMITATIONS OF U SE OF THE G ENERAL D UTY C LAUSE. ..............................................................E.C LASSIFICATION OF V IOLATIONS C ITED U NDER THE G ENERAL D UTY C LAUSE. ..................F. P ROCEDURES FOR I MPLEMENTATION OF S ECTION 5(A)(1) E NFORCEMENT ............................ 4-25 4-27 4-27IV.OTHER-THAN-SERIOUS VIOLATIONS ............................................... 4-28 V.WILLFUL VIOLATIONS. ......................................................................... 4-28A.I NTENTIONAL D ISREGARD V IOLATIONS. ..........................................................................................4-28B.P LAIN I NDIFFERENCE V IOLATIONS. ...................................................................................................4-29 VI. CRIMINAL/WILLFUL VIOLATIONS. ................................................... 4-30A.A REA D IRECTOR C OORDINATION ....................................................................................................... 4-31B.C RITERIA FOR I NVESTIGATING P OSSIBLE C RIMINAL/W ILLFUL V IOLATIONS ........................ 4-31C. W ILLFUL V IOLATIONS R ELATED TO A F ATALITY .......................................................................... 4-32 VII. REPEATED VIOLATIONS. ...................................................................... 4-32A.F EDERAL AND S TATE P LAN V IOLATIONS. ........................................................................................4-32B.I DENTICAL S TANDARDS. .......................................................................................................................4-32C.D IFFERENT S TANDARDS. .......................................................................................................................4-33D.O BTAINING I NSPECTION H ISTORY. .....................................................................................................4-33E.T IME L IMITATIONS..................................................................................................................................4-34F.R EPEATED V. F AILURE TO A BATE....................................................................................................... 4-34G. A REA D IRECTOR R ESPONSIBILITIES. .............................................................................. 4-35 VIII. DE MINIMIS CONDITIONS. ................................................................... 4-36A.C RITERIA ................................................................................................................................................... 4-36B.P ROFESSIONAL J UDGMENT. ..................................................................................................................4-37C. A REA D IRECTOR R ESPONSIBILITIES. .............................................................................. 4-37 IX. CITING IN THE ALTERNATIVE ............................................................ 4-37 X. COMBINING AND GROUPING VIOLATIONS. ................................... 4-37A.C OMBINING. ..............................................................................................................................................4-37B.G ROUPING. ................................................................................................................................................4-38C. W HEN N OT TO G ROUP OR C OMBINE. ................................................................................................4-38 XI. HEALTH STANDARD VIOLATIONS ....................................................... 4-39A.C ITATION OF V ENTILATION S TANDARDS ......................................................................................... 4-39B.V IOLATIONS OF THE N OISE S TANDARD. ...........................................................................................4-40 XII. VIOLATIONS OF THE RESPIRATORY PROTECTION STANDARD(§1910.134). ....................................................................................................... XIII. VIOLATIONS OF AIR CONTAMINANT STANDARDS (§1910.1000) ... 4-43 4-43A.R EQUIREMENTS UNDER THE STANDARD: .................................................................................................. 4-43B.C LASSIFICATION OF V IOLATIONS OF A IR C ONTAMINANT S TANDARDS. ......................................... 4-43 XIV. CITING IMPROPER PERSONAL HYGIENE PRACTICES. ................... 4-45A.I NGESTION H AZARDS. .................................................................................................................................... 4-45B.A BSORPTION H AZARDS. ................................................................................................................................ 4-46C.W IPE S AMPLING. ............................................................................................................................................. 4-46D.C ITATION P OLICY ............................................................................................................................................ 4-46 XV. BIOLOGICAL MONITORING. ...................................................................... 4-47CHAPTER 5CASE FILE PREPARATION AND DOCUMENTATIONI.INTRODUCTION ............................................................................................... 5-1 II.INSPECTION CONDUCTED, CITATIONS BEING ISSUED. .................... 5-1A.OSHA-1 ................................................................................................................................... 5-1B.OSHA-1A. ............................................................................................................................... 5-1C. OSHA-1B. ................................................................................................................................ 5-2 III.INSPECTION CONDUCTED BUT NO CITATIONS ISSUED .................... 5-5 IV.NO INSPECTION ............................................................................................... 5-5 V. HEALTH INSPECTIONS. ................................................................................. 5-6A.D OCUMENT P OTENTIAL E XPOSURE. ............................................................................................................... 5-6B.E MPLOYER’S O CCUPATIONAL S AFETY AND H EALTH S YSTEM. ............................................................. 5-6 VI. AFFIRMATIVE DEFENSES............................................................................. 5-8A.B URDEN OF P ROOF. .............................................................................................................................................. 5-8B.E XPLANATIONS. ..................................................................................................................................................... 5-8 VII. INTERVIEW STATEMENTS. ........................................................................ 5-10A.G ENERALLY. ......................................................................................................................................................... 5-10B.CSHO S SHALL OBTAIN WRITTEN STATEMENTS WHEN: .......................................................................... 5-10C.L ANGUAGE AND W ORDING OF S TATEMENT. ............................................................................................. 5-11D.R EFUSAL TO S IGN S TATEMENT ...................................................................................................................... 5-11E.V IDEO AND A UDIOTAPED S TATEMENTS. ..................................................................................................... 5-11F.A DMINISTRATIVE D EPOSITIONS. .............................................................................................5-11 VIII. PAPERWORK AND WRITTEN PROGRAM REQUIREMENTS. .......... 5-12 IX.GUIDELINES FOR CASE FILE DOCUMENTATION FOR USE WITH VIDEOTAPES AND AUDIOTAPES .............................................................. 5-12 X.CASE FILE ACTIVITY DIARY SHEET. ..................................................... 5-12 XI. CITATIONS. ..................................................................................................... 5-12A.S TATUTE OF L IMITATIONS. .............................................................................................................................. 5-13B.I SSUING C ITATIONS. ........................................................................................................................................... 5-13C.A MENDING/W ITHDRAWING C ITATIONS AND N OTIFICATION OF P ENALTIES. .................................. 5-13D.P ROCEDURES FOR A MENDING OR W ITHDRAWING C ITATIONS ............................................................ 5-14 XII. INSPECTION RECORDS. ............................................................................... 5-15A.G ENERALLY. ......................................................................................................................................................... 5-15B.R ELEASE OF I NSPECTION I NFORMATION ..................................................................................................... 5-15C. C LASSIFIED AND T RADE S ECRET I NFORMATION ...................................................................................... 5-16。

Cap 139N s 3 Presence of prohibited chemicals in food animals三

Cap 139N s 3 Presence of prohibited chemicals infood animals三摘要：本文主要介绍了Cap 139N s 3 Presence of prohibited chemicals in food animals的主要内容。

Cap 139N s 10 Order to recall food animals(1) The Director may order any food animal farmer or food animal trader who has supplied the food animals in respect of which a suspension order is in force to withdraw immediately other food animals of the same batch already supplied and to retrieve, in the manner and to the extent reasonably possible, those animals already supplied.(2) The food animals withdrawn or retrieved under subsection (1) shall be disposed of in such manner as the Director may direct.Cap 139N s 11 Possession of prohibited chemicals, etc.(1) Subject to section 17(7), a food animal farmer who has in his possession or under his control any prohibited chemical commits an offence.(2) Subject to section 17(8), a food animal farmer who has in his possession or under his control fodder containing or mixed with any prohibited chemical commits an offence.(3) Subject to section 17(7), a food animal trader who knowingly and wilfully has in his possession or under his control any prohibited chemical commits an offence.(4) Subject to section 17(8), a food animal trader who knowingly and wilfully has in his possession or under his control fodder containing or mixed with any prohibited chemical commits an offence.Cap 139N s 12 Supply of prohibited chemicals, etc.(1) Subject to section 17(7), a person commits an offence if he supplies or offers to supply any prohibited chemical to any person whom he knows or has reason to believe is a food animal farmer or food animal trader.(2) A person commits an offence if he supplies or offers to supply fodder containing or mixed with any prohibited chemical to any person whom he knows or has reason to believe is a food animal farmer or food animal trader.Cap 139N s 13 Information in respect of fodder(1) No person shall supply or offer to supply any fodder which contains or is mixed with any agricultural and veterinary chemical unless the information set out in subsection (2) is-(a) in the case of the fodder being contained in a package, legibly displayed, in both the English and the Chinese languages, in a conspicuous position on the package; and(b) in any other case, supplied together with the fodder in both the English and the Chinese languages.(2) The information referred to in subsection (1) is-(a) a list of all the agricultural and veterinary chemicals contained or mixed in the fodder and their respective amounts;(b) the instructions for use of the fodder;(c) the withholding period, that is to say, the period of time between feeding the food animal with the fodder for the last time and slaughtering; and(d) the name and address of the fodder supplier.(3) A person commits an offence if he, in purported compliance with the requirement to provide information imposed by subsection (1), provides any information that isincorrect, false or misleading in a material particular and he knows it to be incorrect, false or misleading in a material particular.Cap 139N s 14 Order to suspend supply of fodder(1) Upon receipt of reports or information from the Public Analyst or other sources that-(a) any fodder is suspected of containing-(i) prohibited chemicals;(ii) agricultural and veterinary chemicals at a level that is likely to endanger animals or the health of any person; or(iii) any other substance that is likely to endanger animals or the health of any person; or(b) any fodder is suspected of being supplied without the information required to be furnished under section 13, or where the information is furnished, the information is incorrect, false, misleading or insufficient,the Director may make an order requiring any person who supplies the fodder to suspend the supply of such fodder forthwith for such period as may be reasonably necessary if he considers it in the public interest to do so.(2) The senior veterinary officer, or any person acting under his direction, may destroy or order the forfeiture of any of the fodder in respect of which an order has been made under subsection (1).(3) Where the Director makes an order under subsection (1), he shall forthwith notify the person against whom the order has been made in writing and shall state the reason therefor.Cap 139N s 15 Order to recall fodder(1) The Director may order any person against whom an order has been made under section 14 to withdraw immediately the fodder already supplied and to retrieve, in the manner and to the extent reasonably possible, those fodder already supplied.(2) The fodder withdrawn or retrieved under subsection (1) shall be disposed of in such manner as the Director may direct.Cap 139N s 16 Records to be kept(1) A food animal trader who owns, keeps or sells food animals in a slaughterhouse before their slaughtering shall make a record of the following particulars relating to all transactions whereby such food animals are purchased or sold by him after the food animals are admitted to the slaughterhouse-(a) the date and quantity of each transaction;(b) the names and addresses of the sellers or purchasers; and(c) the identification details required of each food animal, where applicable, under section 7(1).(2) A food animal trader who transports food animals to a slaughterhouse shall make a record of the following particulars relating to the food animals carried by him-(a) the number of food animals involved in each carriage;(b) the name and address of the food animal trader or food animal farmer who employs his service, if applicable; and(c) the identification details required of each food animal, where applicable, under section 7(1).(3) Records required to be made under this section shall be kept for a minimum period of 7 days.。

泊沙康唑美国说明书

HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use NOXAFIL ORAL SUSPENSION safely and effectively. See full prescribing information for NOXAFIL ORAL SUSPENSION. NOXAFIL® (Posaconazole) ORAL SUSPENSION 40 mg/mLInitial U.S. Approval: 2006---------------------------INDICATIONS AND USAGE----------------------------- NOXAFIL is a triazole antifungal agent indicated for: •prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk ofdeveloping these infections due to being severelyimmunocompromised, such as HSCT recipients with GVHD orthose with hematologic malignancies with prolonged neutropenia from chemotherapy. (1.1)•the treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole. (1.2)-------------------------DOSAGE AND ADMINISTRATION---------------------- Indication Dose and Duration of therapyProphylaxis of Invasive Fungal Infections 200 mg (5 mL) three times a day. Duration of therapy is based on recovery from neutropenia or immunosuppression. (2.1)Oropharyngeal Candidiasis (OPC) Loading dose of 100 mg (2.5 mL) twice a day on the first day, then 100 mg (2.5 mL) once a day for 13 days. (2.1)OPC Refractory(rOPC) to Itraconazole and/or Fluconazole 400 mg (10 mL) twice a day. Duration of therapy should be based on the severity of the patient’s underlying disease and clinical response. (2.1)-----------------------DOSAGE FORMS AND STRENGTHS-------------------- NOXAFIL Oral Suspension 40 mg per mL (3)-----------------------------CONTRAINDICATIONS--------------------------------- • Do not administer to persons with known hypersensitivity to posaconazole, any component of NOXAFIL, or other azoleantifungal agents (4.1)• Do not coadminister NOXAFIL with the following drugs;NOXAFIL increases concentrations of:o Sirolimus: can result in sirolimus toxicity (4.2, 7.1)o CYP3A4 substrates (pimozide, quinidine): can result inQTc interval prolongation and rare occurrences of TdP(4.3, 7.2)o Simvastatin: can result in rhabdomyolysis (4.4,7.3)o Ergot alkaloids: can result in ergotism (4.5, 7.4)-----------------------WARNINGS AND PRECAUTIONS------------------------ •Calcineurin Inhibitor Toxicity: NOXAFIL increasesconcentrations of cyclosporine or tacrolimus; reduce dose ofcyclosporine and tacrolimus and monitor concentrationsfrequently. (5.1)•Arrhythmias and QTc Prolongation: NOXAFIL has beenshown to prolong the QTc interval and cause rareoccurrences of TdP. Administer with caution to patients withpotentially proarrhythmic conditions. Do not administer withdrugs known to prolong QTc interval and metabolizedthrough CYP3A4. Correct K+, Mg++, and Ca++ before startingNOXAFIL. (5.2)•Hepatic Toxicity: elevations in LFTs (generally reversible ondiscontinuation) may occur. Discontinuation should beconsidered in patients who develop abnormal LFTs ormonitor LFTs during treatment. (5.3)● Midazolam: NOXAFIL can prolong hypnotic/sedative effects.Monitor patients and benzodiazepine receptor antagonistsshould be available. (5.4, 7.5)-------------------------------ADVERSE REACTIONS------------------------------•Common treatment-emergent adverse reactions (>30%) inprophylaxis studies are fever, diarrhea and nausea.(6.2)• Common treatment-emergent adverse reactions (>5%) incontrolled OPC pool are diarrhea, nausea, headache, andvomiting. Common adverse reactions (>20%) in the refractoryOPC pool are fever, diarrhea, nausea, and vomiting (6.2).To report SUSPECTED ADVERSE REACTIONS, contact ScheringCorporation, a subsidiary of Merck & Co., Inc., at 1-800-526-4099or FDA at 1-800-FDA-1088 or /medwatch.-------------------------------DRUG INTERACTIONS------------------------------Interaction Drug InteractionRifabutin, phenytoin, efavirenz,cimetidine, esomeprazoleAvoid co-administration unlessthe benefit outweighs the risks(7.6, 7.7, 7.8, 7.9)Other drugs metabolized byCYP3A4 (tacrolimus,cyclosporine, vinca alkaloids,calcium channel blockers)Consider dosage adjustment andmonitor for adverse effects andtoxicity (7.1,7.10, 7.11)Digoxin Monitor digoxin plasmaconcentrations (7.12)Metoclopramide Monitor for breakthrough fungalinfections (7.13)--------------------------USE IN SPECIFIC POPULATIONS---------------------• Pregnancy: Based on animal data, may cause fetal harm. (8.1)• Nursing Mothers: Discontinue drug or nursing, taking in toconsideration the importance of drug to the mother. (8.3)• Severe renal impairment: Monitor closely for breakthrough fungalInfections. (8.6)See 17 for PATIENT COUNSELING INFORMATION.Revised:10/2011FULL PRESCRIBING INFORMATION: CONTENTS*1.INDICATIONS AND USAGE1.1 Prophylaxis of Invasive Aspergillus and Candida Infections1.2 Treatment of Oropharyngeal Candidiasis IncludingOropharyngeal Candidiasis Refractory to Itraconazoleand/or Fluconazole2.DOSAGE AND ADMINISTRATION2.1 Dosage2.2 Administration Instructions3.DOSAGE FORMS AND STRENGTHS4.CONTRAINDICATIONS4.2 Use With Sirolimus4.3 QT Prolongation With Concomitant Use With CYP3A4Substrates4.4 Use With Simvastatin4.5 Use With Ergot Alkaloids5.WARNINGS AND PRECAUTIONS5.1 Calcineurin-Inhibitor Drug Interactions5.2Arrhythmias and QT Prolongation5.3 Hepatic Toxicity5.4 Use With Midazolam6.ADVERSE REACTIONS6.1Serious and Otherwise Important Adverse Reactions6.2Clinical Trials Experience6.3 Postmarketing Experience7.DRUG INTERACTIONS7.1 Immunosuppressants Metabolized by CYP3A47.2 CYP3A4 Substrates7.3 HMG-CoA reductase Inhibitors (Statins) Metabolized ThroughCYP3A47.4 Ergot Alkaloids7.5 Benzodiazepines Metabolized by CYP3A47.6 Anti-HIV Drugs7.7 Rifabutin7.8 Phenytoin7.9 Gastric Acid Suppressors/Neutralizers7.10 Vinca Alkaloids7.11 Calcium Channel Blockers Metabolized by CYP3A47.12 Digoxin7.13 Gastrointestinal Motility Agents7.14 GlipizideE IN SPECIFIC POPULATIONS8.1Pregnancy8.3Nursing Mothers8.4Pediatric Use8.5Geriatric Use8.6Renal Insufficiency8.7Hepatic Insufficiency8.8Gender8.9Race10.OVERDOSAGE11.DESCRIPTION12.CLINICAL PHARMACOLOGY12.1 Mechanism of Action12.2 Pharmacodynamics12.3 Pharmacokinetics12.4 Microbiology13. NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility13.2Animal Toxicology and/or Pharmacology14. CLINICAL STUDIES14.1Prophylaxis of Aspergillus and Candida Infections14.2Treatment of Oropharyngeal Candidiasis14.3Treatment of Oropharyngeal Candidiasis Refractory toTreatment With Fluconazole or Itraconazole16.HOW SUPPLIED/STORAGE AND HANDLING17.PATIENT COUNSELING INFORMATION17.1 Administration With Food17.2 Drug Interactions17.3 Serious and Potentially Serious Adverse Reactions17.4See Accompanying FDA-Approved Patient Labeling* Sections or subsections omitted from the full prescribing information are not listed.________________________________________________________FULL PRESCRIBING INFORMATION1. INDICATIONS AND USAGE1.1 Prophylaxis of Invasive Aspergillus and Candida InfectionsNOXAFIL Oral Suspension is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.1.2 Treatment of Oropharyngeal Candidiasis Including Oropharyngeal Candidiasis Refractory to Itraconazole and/or FluconazoleNOXAFIL is indicated for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole.2. DOSAGE AND ADMINISTRATION2.1DosageIndication Dose and Duration of TherapyProphylaxis of Invasive Fungal Infections 200 mg (5 mL) three times a day. The duration of therapy is based on recovery from neutropenia or immunosuppression.Oropharyngeal Candidiasis Loading dose of 100 mg (2.5 mL) twice a day on the first day, then100 mg (2.5 mL) once a day for 13 days.Oropharyngeal Candidiasis Refractory to itraconazole and/or fluconazole 400 mg (10 mL) twice a day. Duration of therapy should be based on the severity of the patient’s underlying disease and clinical response.2.2Administration InstructionsShake NOXAFIL Oral Suspension well before use.Figure 1: A measured dosing spoon is provided, marked for doses of 2.5 mL and 5 mL.It is recommended that the spoon is rinsed with water after each administration and before storage.Each dose of NOXAFIL should be administered with a full meal or with a liquid nutritional supplement or an acidic carbonated beverage (e.g. ginger ale) in patients who cannot eat a full meal.To enhance the oral absorption of posaconazole and optimize plasma concentrations:•Each dose of NOXAFIL should be administered during or immediately (i.e. within 20 minutes) following a full meal. In patients who cannot eata full meal, each dose of NOXAFIL should be administered with a liquid nutritional supplement or an acidic carbonated beverage. For patientswho cannot eat a full meal or tolerate an oral nutritional supplement or an acidic carbonated beverage, alternative antifungal therapy should be considered or patients should be monitored closely for breakthrough fungal infections.•Patients who have severe diarrhea or vomiting should be monitored closely for breakthrough fungal infections.•Co-administration of drugs that can decrease the plasma concentrations of posaconazole should generally be avoided unless the benefit outweighs the risk. If such drugs are necessary, patients should be monitored closely for breakthrough fungal infections [see Drug Interactions(7.6, 7.7, 7.8, 7.9, 7.13)].3. DOSAGE FORMS AND STRENGTHSNOXAFIL Oral Suspension is available in 4-ounce (123 mL) amber glass bottles with child-resistant closures (NDC 0085-1328-01) containing105 mL of suspension (40 mg of posaconazole per mL).4. CONTRAINDICATIONS4.1HypersensitivityNOXAFIL is contraindicated in persons with known hypersensitivity to posaconazole, any component of NOXAFIL, or other azole antifungal agents.4.2 Use With SirolimusNOXAFIL is contraindicated with sirolimus. Concomitant administration of NOXAFIL with sirolimus increases the sirolimus blood concentrations by approximately 9 fold and can result in sirolimus toxicity [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].4.3 QT Prolongation With Concomitant Use With CYP3A4 SubstratesNOXAFIL is contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of NOXAFIL with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and rare occurrences of torsades de pointes [see Warnings and Precautions (5.2) and Drug Interactions (7.2)].4.4 Use With SimvastatinConcomitant administration of NOXAFIL with simvastatin increases the simvastatin plasma concentrations by approximately 10 fold. Increased plasma statin concentrations can be associated with rhabdomyolysis [see Drug Interactions (7.3) and Clinical Pharmacology (12.3)].4.5 Use With Ergot AlkaloidsPosaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism [see Drug Interactions (7.4)].5. WARNINGS AND PRECAUTIONS5.1 Calcineurin-Inhibitor Drug InteractionsConcomitant administration of NOXAFIL with cyclosporine or tacrolimus increases the whole blood trough concentrations of these calcineurin-inhibitors [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. Nephrotoxicity and leukoencephalopathy (including isolated deaths) have been reported in clinical efficacy studies in patients with elevated cyclosporine concentrations. Frequent monitoring of tacrolimus or cyclosporine whole blood trough concentrations should be performed during and at discontinuation of posaconazole treatment and the tacrolimus or cyclosporine dose adjusted accordingly.5.2 Arrhythmias and QT ProlongationSome azoles, including posaconazole, have been associated with prolongation of the QT interval on the electrocardiogram. In addition, rare cases of torsades de pointes have been reported in patients taking posaconazole.Results from a multiple time-matched ECG analysis in healthy volunteers did not show any increase in the mean of the QTc interval. Multiple, time-matched ECGs collected over a 12-hour period were recorded at baseline and steady-state from 173 healthy male and female volunteers (18-85 years of age) administered posaconazole 400 mg BID with a high-fat meal. In this pooled analysis, the mean QTc (Fridericia) interval change from baseline was –5 msec following administration of the recommended clinical dose. A decrease in the QTc (F) interval (–3 msec) was also observed in a small number of subjects (n=16) administered placebo. The placebo-adjusted mean maximum QTc (F) interval change from baseline was <0 msec (–8 msec). No healthy subject administered posaconazole had a QTc (F) interval ≥500 msec or an increase ≥60 msec in their QTc (F) interval from baseline.Posaconazole should be administered with caution to patients with potentially proarrhythmic conditions. Do not administer with drugs that are known to prolong the QTc interval and are metabolized through CYP3A4 [see Contraindications (4.3) and Drug Interactions (7.2)]. Rigorous attempts to correct potassium, magnesium, and calcium should be made before starting posaconazole.5.3 Hepatic ToxicityHepatic reactions (e.g.,mild to moderate elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total bilirubin, and/or clinical hepatitis) have been reported in clinical trials. The elevations in liver function tests were generally reversible on discontinuation of therapy, and in some instances these tests normalized without drug interruption and rarely required drug discontinuation. Isolated cases of more severe hepatic reactions including cholestasis or hepatic failure including deaths have been reported in patients with serious underlying medical conditions (e.g., hematologic malignancy) during treatment with posaconazole. These severe hepatic reactions were seen primarily in subjects receiving the 800 mg daily (400 mg BID or 200 mg QID) in clinical trials.Liver function tests should be evaluated at the start of and during the course of posaconazole therapy. Patients who develop abnormal liver function tests during posaconazole therapy should be monitored for the development of more severe hepatic injury. Patient management should include laboratory evaluation of hepatic function (particularly liver function tests and bilirubin). Discontinuation of posaconazole must be considered if clinical signs and symptoms consistent with liver disease develop that may be attributable to posaconazole.5.4 Use With MidazolamConcomitant administration of NOXAFIL with midazolam increases the midazolam plasma concentrations by approximately 5 fold. Increased plasma midazolam concentrations could potentiate and prolong hypnotic and sedative effects. Patients must be monitored closely for adverse effects associated with high plasma concentrations of midazolam and benzodiazepine receptor antagonists must be available to reverse these effects [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)].6. ADVERSE REACTIONS6.1 Serious and Otherwise Important Adverse ReactionsThe following serious and otherwise important adverse reactions are discussed in detail in another section of the labeling: • Hypersensitivity[see Contraindications (4.1)]•Arrhythmias and QT Prolongation [see Warnings and Precautions (5.2)][see Warnings and Precautions (5.3)]• HepaticToxicity6.2 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of NOXAFIL cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.The safety of posaconazole therapy has been assessed in 1844 patients in clinical trials. This includes 605 patients in the active-controlled prophylaxis studies, 557 patients in the active-controlled OPC studies, 239 patients in refractory OPC studies, and 443 patients from other indications. Thisrepresents a heterogeneous population, including immunocompromised patients, e.g., patients with hematological malignancy, neutropenia post-chemotherapy, graft vs. host disease post hematopoietic stem cell transplant, and HIV infection, as well as non-neutropenic patients. This patient population was 71% male, had a mean age of 42 years (range 8-84 years, 6% of patients were ≥65 years of age and 1% was <18 years of age), and were 64% white, 16% Hispanic, and 36% non-white (including 14% black). Posaconazole therapy was given to 171 patients for ≥6 months, with 58 patients receiving posaconazole therapy for ≥12 months. Table 1 presents treatment-emergent adverse reactions observed at an incidence of >10% in posaconazole prophylaxis studies. Table 2 presents treatment-emergent adverse reactions observed at an incidence of at least 10% in the OPC/rOPC studies.Prophylaxis of Aspergillus and Candida: In the 2 randomized, comparative prophylaxis studies, the safety of posaconazole 200 mg threetimes a day was compared to fluconazole 400 mg once daily or itraconazole 200 mg twice a day in severely immunocompromised patients.The most frequently reported adverse reactions (>30%) in the prophylaxis clinical trials were fever, diarrhea and nausea.The most common adverse reactions leading to discontinuation of posaconazole in the prophylaxis studies were associated with GI disorders,specifically, nausea (2%), vomiting (2%), and hepatic enzymes increased (2%).TABLE 1: Study 1 and Study 2. Number (%) of Randomized Subjects Reporting Treatment-Emergent Adverse Reactions: Frequency of at Least 10% in the Posaconazole or Fluconazole Treatment Groups (Pooled Prophylaxis Safety Analysis)Body SystemPreferred Term Posaconazole(n=605)Fluconazole(n=539)Itraconazole(n=58)Subjects Reporting any Adverse Reaction 595 (98) 531 (99) 58 (100) Body as a Whole - General DisordersFever 274 (45) 254 (47) 32 (55) Headache 171 (28) 141 (26) 23 (40) Rigors 122 (20) 87 (16) 17 (29) Fatigue 101 (17) 98 (18) 5 (9) Edema Legs 93 (15) 67 (12) 11 (19) Anorexia 92 (15) 94 (17) 16 (28) Dizziness 64 (11) 56 (10) 5 (9) Edema 54 (9) 68 (13) 8 (14) Weakness 51 (8) 52 (10) 2 (3) Cardiovascular Disorders, GeneralHypertension 106 (18) 88 (16) 3 (5) Hypotension 83 (14) 79 (15) 10 (17) Disorders of Blood and Lymphatic SystemAnemia 149 (25) 124 (23) 16 (28) Neutropenia 141 (23) 122 (23) 23 (40) Febrile Neutropenia 118 (20) 85 (16) 23 (40) Disorders of the Reproductive System and BreastVaginal Hemorrhage* 24 (10) 20 (9) 3 (12) Gastrointestinal System DisordersDiarrhea 256 (42) 212 (39) 35 (60) Nausea 232 (38) 198 (37) 30 (52) Vomiting 174 (29) 173 (32) 24 (41) Abdominal Pain 161 (27) 147 (27) 21 (36) Constipation 126 (21) 94 (17) 10 (17) Mucositis NOS 105 (17) 68 (13) 15 (26) Dyspepsia 61 (10) 50 (9) 6 (10) Heart Rate and Rhythm DisordersTachycardia 72 (12) 75 (14) 3 (5) Infection and InfestationsBacteremia 107 (18) 98 (18) 16 (28) Herpes Simplex 88 (15) 61 (11) 10 (17) Cytomegalovirus Infection 82 (14) 69 (13) 0Pharyngitis 71 (12) 60 (11) 12 (21)Upper Respiratory Tract Infection 44 (7) 54 (10) 5 (9)Liver and Biliary System DisordersBilirubinemia 59 (10) 51 (9) 11 (19)Metabolic and Nutritional DisordersHypokalemia 181 (30) 142 (26) 30 (52)Hypomagnesemia 110 (18) 84 (16) 11 (19)Hyperglycemia 68 (11) 76 (14) 2 (3)Hypocalcemia 56 (9) 55 (10) 5 (9)Musculoskeletal System DisordersMusculoskeletal Pain 95 (16) 82 (15) 9 (16)Arthralgia 69 (11) 67 (12) 5 (9)Back Pain 63 (10) 66 (12) 4 (7)Platelet, Bleeding and Clotting DisordersThrombocytopenia 175 (29) 146 (27) 20 (34)Petechiae 64 (11) 54 (10) 9 (16)Psychiatric DisordersInsomnia 103 (17) 92 (17) 11 (19)Anxiety 52 (9) 61 (11) 9 (16)Respiratory System DisordersCoughing 146 (24) 130 (24) 14 (24)Dyspnea 121 (20) 116 (22) 15 (26)Epistaxis 82 (14) 73 (14) 12 (21)Skin and Subcutaneous Tissue DisordersRash 113 (19) 96 (18) 25 (43)Pruritus 69 (11) 62 (12) 11 (19)* Percentages of sex-specific adverse reactions are based on the number of males/females.NOS = not otherwise specified.HIV Infected Subjects With OPC: In 2 randomized comparative studies in OPC, the safety of posaconazole at a dose of ≤400 mg QD in 557 HIV-infected patients was compared to the safety of fluconazole in 262 HIV-infected patients at a dose of 100 mg QD.An additional 239 HIV-infected patients with refractory OPC received posaconazole in 2 non-comparative trials for refractory OPC (rOPC).Of these subjects, 149 received the 800-mg/day dose and the remainder received the ≤400-mg QD dose.In the OPC/rOPC studies, the most common adverse reactions were fever, diarrhea, nausea, headache, and vomiting.The most common adverse reactions that led to treatment discontinuation of posaconazole in the Controlled OPC Pool included respiratory insufficiency (1%) and pneumonia (1%). In the refractory OPC pool, the most common adverse reactions that led to treatment discontinuation of posaconazole were AIDS (7%) and respiratory insufficiency (3%).TABLE 2: Treatment-Emergent Adverse Reactions With Frequency of at Least 10% in OPC Studies (Treated Population)Number (%) of SubjectsControlled OPC Pool Refractory OPC PoolPosaconazole Fluconazole PosaconazoleBody SystemPreferred Term n=557 n=262 n=239356 (64) 175 (67) 221 (92)Subjects Reporting any AdverseReaction*Body as a Whole – General DisordersFever 34 (6) 22 (8) 82 (34)Headache 44 (8) 23 (9) 47 (20)Anorexia 10 (2) 4 (2) 46 (19)Fatigue 18 (3) 12 (5) 31 (13)Asthenia 9 (2) 5 (2) 31 (13)Rigors 2 (<1) 4 (2) 29 (12)Pain 4 (1) 2 (1) 27 (11)Disorders of Blood and Lymphatic SystemNeutropenia 21 (4) 8 (3) 39 (16)Anemia 11 (2) 5 (2) 34 (14)Gastrointestinal System DisordersDiarrhea 58 (10) 34 (13) 70 (29)Nausea 48 (9) 30 (11) 70 (29)Vomiting 37 (7) 18 (7) 67 (28)Abdominal Pain 27 (5) 17 (6) 43 (18)Infection and InfestationsCandidiasis, Oral 3 (1) 1 (<1) 28 (12)Herpes Simplex 16 (3) 8 (3) 26 (11)Pneumonia 17 (3) 6 (2) 25 (10)Metabolic and Nutritional DisordersWeight Decrease 4 (1) 2 (1) 33 (14)Dehydration 4 (1) 7 (3) 27 (11)Psychiatric DisordersInsomnia 8 (1) 3 (1) 39 (16)Respiratory System DisordersCoughing 18 (3) 11 (4) 60 (25)Dyspnea 8 (1) 8 (3) 28 (12)Skin and Subcutaneous Tissue DisordersRash 15 (3) 10 (4) 36 (15)Sweating Increased 13 (2) 5 (2) 23 (10)OPC=oropharyngeal candidiasis; SGOT=serum glutamic oxaloacetic transaminase (same as AST);SGPT=serum glutamic pyruvic transaminase (same as ALT).* Number of subjects reporting treatment-emergent adverse reactions at least once during the study,without regard to relationship to treatment. Subjects may have reported more than 1 event.Adverse reactions were reported more frequently in the pool of patients with refractory OPC. Among these highly immunocompromised patients with advanced HIV disease, serious adverse reactions (SARs) were reported in 55% (132/239). The most commonly reported SARs were fever (13%) and neutropenia (10%).Less Common Adverse Reactions: Clinically significant adverse reactions reported during clinical trials in prophylaxis, OPC/rOPC or other trials with posaconazole which occurred in less than 5% of patients are listed below:•Blood and lymphatic system disorders: hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, neutropenia aggravated •Endocrine disorders: adrenal insufficiency•Nervous system disorders: paresthesia•Immune system disorders: allergic reaction [see Contraindications (4.1)]•Cardiac disorders: Torsades de pointes [see Warnings and Precautions (5.2)]•Vascular disorders: pulmonary embolism•Liver and Biliary System Disorders: bilirubinemia, hepatic enzymes increased, hepatic function abnormal, hepatitis, hepatomegaly, jaundice, SGOT Increased, SGPT Increased•Metabolic and Nutritional Disorders: Hypokalemia•Platelet, Bleeding, and Clotting Disorders: Thrombocytopenia•Renal & Urinary System Disorders: Renal Failure AcuteClinical Laboratory Values: In healthy volunteers and patients, elevation of liver function test values did not appear to be associated with higher plasma concentrations of posaconazole. The majority of abnormal liver function tests were minor, transient, and did not lead to discontinuation of therapy.For the prophylaxis studies, the number of patients with changes in liver function tests from Common Toxicity Criteria (CTC) Grade 0, 1, or 2 at baseline to Grade 3 or 4 during the study is presented in Table 3.TABLE 3: Study 1 and Study 2. Changes in Liver Function Test Results From CTC Grade 0, 1, or 2 at Baseline to Grade 3 or 4Number (%) of Patients With Change*Study 1Laboratory Parameter Posaconazolen=301Fluconazolen=299AST 11/266 (4) 13/266 (5)Number (%) of Patients With Change*ALT 47/271 (17) 39/272 (14) Bilirubin 24/271 (9) 20/275 (7) Alkaline Phosphatase 9/271 (3) 8/271 (3)Study 2Laboratory Parameter Posaconazole(n=304)Fluconazole/Itraconazole(n=298)AST 9/286 (3) 5/280 (2)ALT 18/289 (6) 13/284 (5)Bilirubin 20/290 (7) 25/285 (9)Alkaline Phosphatase 4/281 (1) 1/276 (<1)* Change from Grade 0 to 2 at baseline to Grade 3 or 4 during the study.These data are presented in the form X/Y, where X represents the numberof patients who met the criterion as indicated, and Y represents the numberof patients who had a baseline observation and at least one post-baselineobservation.CTC = Common Toxicity Criteria; AST= Aspartate Aminotransferase;ALT= Alanine Aminotransferase.The number of patients treated for OPC with clinically significant liver function test (LFT) abnormalities at any time during the studies is provided in Table 4. (LFT abnormalities were present in some of these patients prior to initiation of the study drug).TABLE 4: Clinically Significant Laboratory Test Abnormalities Without Regard to Baseline ValueControlled RefractoryPosaconazole Fluconazole PosaconazoleLaboratory Test n= 557(%) n=262(%) n=239(%)ALT > 3.0 x ULN 16/537 (3) 13/254 (5) 25/226 (11)AST > 3.0 x ULN 33/537 (6) 26/254(10)39/223 (17)Total Bilirubin > 1.5 x ULN 15/536 (3) 5/254 (2) 9/197 (5)Alkaline Phosphatase > 3.0 x ULN 17/535 (3) 15/253 (6) 24/190 (13)ALT= Alanine Aminotransferase; AST= Aspartate Aminotransferase.6.3 Postmarketing ExperienceNo clinically significant postmarketing adverse reactions were identified that have not previously been reported during clinical trials experience.7. DRUG INTERACTIONSPosaconazole is primarily metabolized via UDP glucuronidation and is a substrate of p-glycoprotein efflux. Therefore, inhibitors or inducers of these clearance pathways may affect posaconazole plasma concentrations. Posaconazole is also a strong inhibitor of CYP3A4. Therefore, plasma concentrations of drugs predominantly metabolized by CYP3A4 may be increased by posaconazole [see Clinical Pharmacology (12.3)].7.1 Immunosuppressants Metabolized by CYP3A4Sirolimus: Concomitant administration of posaconazole with sirolimus increases the sirolimus blood concentrations by approximately 9 fold and can result in sirolimus toxicity. Therefore, posaconazole is contraindicated with sirolimus [see Contraindications (4.2) and Clinical Pharmacology (12.3)].Tacrolimus: Posaconazole has been shown to significantly increase the C max and AUC of tacrolimus. At initiation of posaconazole treatment, reduce the tacrolimus dose to approximately one-third of the original dose. Frequent monitoring of tacrolimus whole blood trough concentrations should be performed during and at discontinuation of posaconazole treatment and the tacrolimus dose adjusted accordingly [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].Cyclosporine: Posaconazole has been shown to increase cyclosporine whole blood concentrations in heart transplant patients upon initiation of posaconazole treatment. It is recommended to reduce cyclosporine dose to approximately three-fourths of the original dose upon initiation of posaconazole treatment. Frequent monitoring of cyclosporine whole blood trough concentrations should be performed during and at discontinuation of posaconazole treatment and the cyclosporine dose adjusted accordingly [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].7.2 CYP3A4 SubstratesConcomitant administration of posaconazole with CYP3A4 substrates such as pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and rare occurrences of torsades de pointes. Therefore, posaconazole is contraindicated with these drugs. [see Contraindications (4.3), and Warnings and Precautions (5.2)].。

PROMAFOUR 自凝钙硅酸板产品说明书

Supersedes : 0 / 0 / 01.1. Product identifierTrade name:PROMAFOUR®Identification of the product:Self-supporting calcium silicate board.Type of product:Article.1.2. Relevant identified uses of the substance, mixture or article and uses advised against Use:High temperature insulation.1.3. Details of the supplier of the safety data sheetCompany identification:Promat UK LtdThe Sterling CentreEastern Road - BerkshireRG12 2TD Bracknell UNITED KINGDOMTel.: +44 (0) 1344 381400Fax: +44 (0) 1344 3814011.4. Emergency telephone numberEmergency phone nr:+44 (0) 1344 381 400Symptoms relating to use:For the installed product in its final application: no hazards known.During machining the product (drilling, cutting, sanding, etc.), airborne dust can bereleased.- Inhalation:As with most types of nuisance dust, excessive inhalation of dust may causeirritation of the bronchial tubes.The handling and machining of this product may lead to the release of quartzcontaining dust. The inhalation of dust containing quartz, in particular the fine (respirable) dust fraction, in high concentrations or over a prolonged period of timemay lead to lung disease (silicosis) and an increased risk of lung cancer.Long term hazards: see section 11.- Skin contact:Prolonged skin contact may lead to skin irritation for sensitive persons.- Eye contact:Eye contact with dust may lead to transient eye irritation or inflammation.- Ingestion:Not expected to present a significant ingestion hazard under anticipated conditionsof normal use.2.1. Classification of the substance or mixtureClassification EC 67/548 or EC 1999/45This product is classified as not hazardous.Hazard Class and Category Code Regulation EC 1272/2008 (CLP)This product is classified as not hazardous.2.2. Label elementsLabelling EC 67/548 or EC 1999/45Supersedes : 0 / 0 / 0No labelling required.Labelling Regulation EC 1272/2008 (CLP)No labelling required.2.3. Other hazardsNone under normal conditions.Components:This article is classified as not hazardous.This product is a manufactured article, not a substance nor a preparation.Substance name Contents CAS No EC No Annex No Ref REACH ClassificationWollastonite:13983-17-0237-772-5----------Not classified. (DSD/DPD)----------------------------------Not classified. (GHS)Cellulose fibers:65996-61-4265-995-8----------Not classified. (DSD/DPD)----------------------------------Undefined. (GHS)Quartz (SiO2):14808-60-7238-878-4----------Not classified. (DSD/DPD)----------------------------------Not classified. (GHS)Crystalline calcium silicate hydrate:1344-95-2215-710-8----------Not classified. (DSD/DPD)----------------------------------Undefined. (GHS)Vermiculite:1318-00-9---------------Not classified. (DSD/DPD)----------------------------------Not classified. (GHS)4.1. Description of first aid measuresFirst aid measures- Inhalation:Remove to fresh air and drink water.- Skin contact:Rinse the skin with water.- Eye contact:Do not rub the eye. Rinse the eye out with plenty of clean water for at least 15minutes. If eye irritation or inflammation persists, seek medical advice.- Ingestion:Drink water.4.2. Most important symptoms and effects, both acute and delayedSee sections 7 and 8.4.3. Indication of any immediate medical attention and special treatment neededNo data available.5.1. Extinguishing mediaSuitable extinguishing media:All extinguishing media can be used.5.2. Special hazards arising from the substance or mixtureSupersedes : 0 / 0 / 0Nothing to report.5.3. Advice for fire-fightersFlammable class:The product is non-combustible.Protection against fire:Do not enter fire area without proper protective equipment, including respiratoryprotection.6.1. Personal precautions, protective equipment and emergency proceduresPersonal precautions:Minimize generation of dust. Avoid breathing dusts. Avoid eye and skin contact.Use recommended respiratory protection.6.2. Environmental precautionsEnvironmental precautions:Prevent spread of dust.6.3. Methods and material for containment and cleaning upMethods and material for containment:Use closed containers to avoid dust release.Clean up methods:Shovel up small pieces. Dampen down any dust before putting into appropriateskips.6.4. Reference to other sectionsSee sections 7 and 8.7.1. Precautions for safe handlingPersonal protection:Dust, generated during machining and processing must be exhausted and theregulatory occupational exposure limits (workplace exposure limits in UK) for totaland respirable dust and respirable quartz dust must be respected.Use always respiratory protective equipment when exposures are likely or can beforeseen to exceed the Occupational Exposure Limits or Workplace ExposureLimits in UK (refer to local regulations).Collect dust with a vacuum cleaner or soak with water before sweeping up. Technical protective measures:Work in a well ventilated areaUse tools with appropriate dust exhaust equipment.7.2. Conditions for safe storage, including any incompatibilitiesStorage:Store in dry, covered and frost proof area.7.3. Specific end use(s)Fire protection in buildings. High temperature insulation.Supersedes : 0 / 0 / 08.1 Control parametersOccupational Exposure Limits:When machining boards (drilling, cutting, sanding, etc.), respect Occupational (UK: Workplace Exposure Limits)Exposure Limits (OEL) or Workplace Exposure Limits (WEL in the UK) for inhalableand respirable dust and for respirable quartz dust.Check the latest Occupational Exposure Limits (OEL) or Workplace ExposureLimits (WEL in the UK) for airborne contaminants that are applicable in yourcountry.Typical Occupational Exposure Limits or Workplace Exposure Limits in the UK (8hrs TWA) and Ireland on the date of issue of this document are:Control parameters for airborn:- Quartz dust (CAS number: 14808 - 60 - 7):contaminants - Respirable: 0.1 mg/m³(UK) - 0.05 mg/m³ (IE)- Particles not otherwise classified or regulated (nuisance dust)- Inhalable: 10 mg/m³.- Respirable: 4 mg/m³.8.2 Occupational exposure controls8.2.1 General protection controls- Industrial hygiene:Ensure vacuum dust exhaust with correct filter when using motorised machiningtools.8.2.2. Individual protection controls- Respiratory protection:Avoid breathing dusts.Use appropriate respiratory equipment when exposures are likely or can beforeseen to exceed the Occupational Exposure Limits or Workplace ExposureLimits for the UK (e.g. for exposures up to 10 times the OEL (WEL) use at least aP2 type duct mask. For higher exposure, use a P3 type mask).- Skin protection:Avoid contact with skin.Use working clothes and gloves to protect against mechanical injury and direct skincontact.- Eye protection:Avoid contact with eyes.Use safety glasses whenever tools are used and dusts are produced.- Ingestion:When using, do not eat, drink or smoke.• Appearance:Board (solid)• Physical state at 20 °C:Solid.• Colour:White-beige• Odour:None.• pH value:10 - 11• Flammability:Non flammable.• Density:ca. 950 kg/m3• Solubility in water:Insoluble.• Other properties:Information on other physical and chemical properties, as listed in the section 9.1 ofAnnex II of the Commission Regulation EU 453/2010 of 20 May 2010 is notavailable10.1. ReactivitySupersedes : 0 / 0 / 0Stability and reactivity:Stable under normal conditions.10.2. Chemical stabilityChemical stability:Stable under normal conditions of storage, handling and use.10.3. Possibility of hazardous reactionsHazardous reactions:None.Hazardous properties:None10.4. Conditions to avoidConditions to avoid:None known.10.5. Incompatible materialsMaterials to avoid:Strong acids.10.6. Hazardous decomposition productsNone known.11.1. Information on toxicological effectsToxicity information:No data available.Acute toxicity:No acute toxicity has been reported, apart from some exceptional cases oftransient eye irritation or inflammation, skin irritation or irritation of the mucosae (throat, bronchial tubes) by excessive exposure to dust.11.2 Additional information:• On product:The inhalation of quartz containing dust, in particular the fine dust fraction(respirable size), in high concentrations or over repeated or prolonged periods oftime can be hazardous to health and may lead to chronic lung disease and anincreased risk of lung cancer. This risk will be minimal if correct working practicesare observed and applied. (Refer to Section 8). However, for this product, withexposure assessments performed by accredited European laboratories usingreference workplace monitoring methods, any quartz levels in the respirable dustwere below the detection limit.According to the International Agency for Research on Cancer (IARC MonographVolume 100C - 2012) “Crystalline silica inhaled in the form of quartz or cristobaliteis carcinogenic to humans(Group 1).”12.1. ToxicityNo known effects.12.2. Persistence - degradabilitySupersedes : 0 / 0 / 0No data available.12.3. Bioaccumulative potentialNo data available.12.4. Mobility in soilNo data available.12.5. Results of PBT and vPvB assessmentNo data available.12.6. Other adverse effectsNo information available.Ecological effects information:No data available.13.1. Waste treatment methodsHandle as construction industry waste.13.2. GeneralProduct disposal:Dispose in a safe manner in accordance with local/national regulations. Packaging disposal:Dispose according to local legislation.EWC (European Waste Catalogue) -:170107N°.General information:Not classified as dangerous in the meaning of transport regulations.Symbol(s):None.R Phrase(s):None.S Phrase(s):None.Further information:None.DISCLAIMER OF LIABILITYThe information in this SDS was obtained from sources which we believe are reliable. However, the information is provided without any warranty, express or implied, regarding its correctness. The conditions or methods of handling, storage, use or disposal of the product are beyond our control and may be beyond our knowledge. For this and other reasons, we do not assume responsibility and expressly disclaim liability for loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of the product. This SDS was prepared and is to be used only for this product. If the product is used as a component in another product, this SDS information may not be applicable.This data sheet and the information it contains is not intended to supersede any terms or conditions of sale and does notSupersedes : 0 / 0 / 0constitute a specification. Nothing contained herein is to be construed as a recommendation for use in violation of any patent or applicable laws or regulations.The contents and format of this SDS are in accordance with REGULATION (EC) No 1907/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCILEnd of document。

NOTIFIRE WEB SERVER NWS-3 说明书

NWS-3NOTI•FIRE•NET™Web ServerDN-6928:C • A0-810GeneralThe NOTI•FIRE•NET™ Web Server(NWS-3) is a web-baseddevice that acts as an HTML server, allowing remote access tothe NOTI•FIRE•NET™ network via the Internet or an intranet.With the NWS-3 interface, users can view fire alarm controlpanel (FACP) event history, event status, device properties andother information based on access permissions defined by thesystem administrator. All data available on the NWS-3 is a“snapshot” of the data on the NOTI•FIRE•NET™ network atthe time the browser requested the information.The NWS-3 interfaces to the Internet/intranet using an IP-basedwire Ethernet connection.FeaturesFOR THE NOTI•FIRE•NET™ WEB SER ER ANDBROWSER CONFIGURATION TOOL•Access NOTI•FIRE•NET™ device statuses and properties remotely via the Internet or an intranet.•Automatically send up to 50 emails or text messages in response to any system event.•Compatible with standard and high speed NOTI•FIRE•NET™.•Unacknowledged Beep feature, if enabled, causes the com-puter browsing the NWS-3 to beep at three-second intervals if there are unacknowledged events in the Multiple Event List.•Compatible with NOTI•FIRE•NET™ version 5.0 and higher.•One NWS-3 supports multiple users.•Standard Ethernet over IP connection.•Y our system remains secure by installing the NWS-3 behind your network firewall.•Supports up to 64 operator and 64 administrator accounts.•Built-in password security and user-access record.•Multiple users can access the web server at the same time.•Supports standard Microsoft® Internet Explorer 8.0 or higher.•Intuitive Explorer-style user interface.•Ability to use V eriFire® Tools (version 3.0 or higher) for remote programming/configuration of the NWS-3 and ONYX® Series products.NOTE: No fire alarm control functions are permitted. The NWS-3 is an ancillary device and not intended for primary reporting.CompatibilityThe NWS-3 is compatible with NOTI•FIRE•NET™ version 5.0 and higher for the following panels and devices:•ONYX® Series.•AM2020/AFP1010 (version 5.0 SIB).•AFP-200 (events only).•AFP-300/AFP-400.•BACnet Gateway (events only).•NCS Network Control Station (events only).•NCA(-2) Network Control Annunciator (events only).•Compatible with high speed network HS-NCM version 1.0 and higher.NOTE: The NWS-3 is NOT intended as a primary annunciator and is ancillary in nature.System Requirements•NOTI•FIRE•NET™ Web Server (NWS-3).•NCM card.•Browser: Microsoft Internet Explorer, version 8.0 or higher.•JAVA version 6 or later.Agency Listings and ApprovalsThese listings and approvals apply to the NOTI•FIRE•NET™Web Server. In some cases, certain modules or applications may not be listed by certain approval agencies, or listing may be in process. Consult factory for latest listing status.•UL/ULC Listed: S635.•CSFM: 7165-0028:0247.•FDNY: COA#6045.NFN-GW-EM-3.JPGDN-6928:C • 08/15/2012 — Page 1 of 2Page 2 of 2 — DN-6928:C • 08/15/2012ONYX ®, NOTIFIER ®, and VeriFire ® are registered trademarks, and NOTI•FIRE•NET ™ and ONYXWorks ™ are trademarks of Honeywell International Inc. Microsoft ® and Windows ® are registered trademarks of Microsoft Corporation.©2012 by Honeywell International Inc. All rights reserved. Unauthorized use of this document is strictly prohibited.This document is not intended to be used for installation purposes. We try to keep our product information up-to-date and accurate. We cannot cover all specific applications or anticipate all requirements.All specifications are subject to change without notice.For more information, contact Notifier. Phone: (203) 484-7161, FAX: (203) 484-7118.System Architecture•Connect to the NOTI•FIRE•NET™ network. The NWS-3can be connected to the NOTI•FIRE•NET™ network via the Network Control Module (NCM) network interface card (see diagram).•The NWS-3 can be directly connected to ONYX® series pan-els for stand-alone panel applications.•The NWS-3 can also be connected to high speed networks using HS-NCM network interface.System Architecture DiagramNWS -3 HS-NCM OR NCM ARCHITECTURECAB-4 Cabinet with NWS-3 Assembly and HS-NCM W/SF/MF or NCM W/F BoardNFN NetworkInternet/IntranetSupported FACP Supported FACPPC Browser InterfaceHS-NCM-W/SF/MFor NCM-W/FHS-NCM-W/SF/MF or NCM-W/FNWS-3 DIRECT PANEL ARCHITECTUREInternet/IntranetPC Browser InterfaceSupported ONYX Series FACPwith Web Server Assembly。

细胞凋亡相关蛋白研究进展

2、BCL- 2 家族蛋白
Bcl-2被以为是细胞凋亡蛋白家族中最主要旳调控蛋白。它们在线粒体参加旳凋亡途径中起调控作用，能控制线粒体中细胞色素c等凋亡因子旳释放。
Bcl- 2 家族分为两大类: 一类是抗凋亡蛋白, 主要涉及Bcl- 2、Bcl- xL 和 Bcl- w等; 另一类是促凋亡蛋白, 主要涉及 Bax、Bak、Bid、Bim 和 Bad 等。
在线粒体损伤后，细胞色素C从构建旳孔隙中进入细胞液，与抗恶性贫血因子1和caspase-9构成了凋亡复合体。在caspase-9被激活后，再作用于其下游旳 caspase-3酶原，活化旳caspase-3作为效应子，作用于不同旳靶分子，经蛋白水解作用造成细胞凋亡。
3、P53蛋白
肿瘤克制蛋白 p53 在维持蛋白组旳完整性中起着主要旳作用。p53 作为一种转录因子对 DNA损伤做出反应,并诱导下游蛋白如 p21, Mdm2 和 Bax 旳体现, 这些下游蛋白能够调整细胞周期和凋亡。正常旳 p53 在细胞里旳功能有多种, 但目前研究最多旳有两种, 一种是克制细胞分裂, 让其停留在细胞周期旳 Gl 期,另一种是使细胞凋亡, 此两种功能与 p53 转录旳能力都有一定程度旳联络。
细胞凋亡有关蛋白旳研究进展
序言：
细胞凋亡是细胞旳一种基本生物学现象, 在多细胞生物清除不需要旳或异常旳细胞中起着必要旳作用。
细胞凋亡是多蛋白严格控制旳过程, 伴随分子生物学技术旳发展对多种细胞凋亡旳过程有了较为进一步旳认识, 但是迄今为止凋亡过程确切机制尚不完全清楚。
细胞凋亡是一种主动过程,它涉及一系列蛋白旳激活、体现以及调控等旳作用。其中 caspase 家族蛋白、Bcl- 2 家族蛋白和 p53 蛋白、 survivin 蛋白等在凋亡旳信号转导中扮演着主要角色。

被害人参加国际刑事法院诉讼的申请及其审查

分庭对申请的审查和处理。
一被害人填写并提交申请表
根据《规则》第８９条的规定，国际刑事法院采取被害人申请参加诉讼的制度。简言之，被
害人必须通过书记官处提出参加的申请，获得相关分庭的准许后方能参加。申请参加的具体程序
为：被害人向书记官长提交申请书，书记官长收到申请后，将该申请书转交给相关分庭，同时给
ＩＣＣ，ＳｉｔｕａｔｉｏｎｉｎＵｇａｎｄａ， “Ｄｅｃｉｓｉｏｎｏｎｖｉｃｔｉｍｓａｐｐｌｉｃａｔｉｏｎｓｆｏｒｐａｒｔｉｃｉｐａｔｉｏｎａ／００１０／０６，ａ／００６４／０６ｔｏａ／００７０／０６，ａ／００８１／０６，
ａ／００８２／０６，ａ／００８４／０６ｔｏａ／００８９／０６，ａ／００９１／０６ｔｏａ／００９７／０６，ａ／００９９／０６，ａ／０１００／０６，ａ／０１０２／０６ｔｏａ／０１０４／０６，ａ／０１１１／
０６，ａ／０１１３／０６ｔｏａ／０１１７／０６，ａ／０１２０／０６，ａ／０１２１／０６ａｎｄａ／０１２３／０６ｔｏａ／０１２７／０６”，１４Ｍａｒｃｈ２００８，ｐａｒａｓ４－６
ＩＣＣ，ＰｒｏｓｅｃｕｔｏｒｖＬｕｂａｎｇａ，ＩＣＣ⁃０１／０４⁃０１／０６⁃６０１⁃ｔＥＮ，６Ｏｃｔｏｂｅｒ２００６，ｐ８
ａｎｄｔｈｅＯｆｆｉｃｅｏｆＰｕｂｌｉｃＣｏｕｎｓｅｌｆｏｒｔｈｅＤｅｆｅｎｃｅａｇａｉｎｓｔＰｒｅ－ＴｒｉａｌＣｈａｍｂｅｒＩｓＤｅｃｉｓｉｏｎｏｆ６Ｄｅｃｅｍｂｅｒ２００７” ，１８Ｊｕｎｅ２００８，

METTLER TOLEDO智能光学溶解氧传感器说明书

More Uptime, Reduced Cost of Ownership with Optical DO MeasurementThe fast response, excellent signal stability, and low maintenance ofMETTLER TOLEDO’s intelligent optical dissolved oxygen sensors will helpyou produce a higher quality product and save on costs.Keeping oxygen at a minimum Oxygen can be detrimental to beer quality: Its presence can oxidize flavorings, allow the growth of microorganisms, and reduce shelf life. Moreover, longer distribution channels have put increasing pressure on breweries to minimize dissolved oxygen in products. Therefore, filler line, filtration, blending, and deaeration processes re-quire oxygen measurement systems with high accuracy at very low levels in order that any increase in oxygen concentration can be detected immediately. Of equal importance, time required for O2 sensor maintenance must be kept short due to the cost of unplanned process interruptions. Innovative optical dissolved oxygen systemThe InPro 6970 i optical O2sensor is highly accurate at ppb O2 levels, offers avery fast response time, and is also ex-tremely easy to maintain.Some amperometric systems require up to10 minutes after a Clean-in-Place (CIP)cycle before they produce a stable reading.The 20 second response time of theInPro 6970 i enables fast start up of thefilling process after a switch from rinsingwater to beer, and consequently, beerlosses are reduced.Simple maintenance, fastcalibrationOptical oxygen sensors are also character-ized by their easy maintenance: Instead ofmembrane body, inner body, and electro-lyte that have to be replaced on ampero-metric sensors, the InPro 6970 i has only21NewsBreweryPerspectives in Liquid Process AnalyticsINGOLDLeading Process Analytics2METTLER TOLEDOBrewery News 21one consumable component, the OptoCap. It contains a fluorescing, oxygen-sensitive membrane which is the key to the sensor’s superb accuracy and speed of response. Replacement of the OptoCap can be done by even un-skilled personnel in only a few minutes. In typical applications, the OptoCap needs to be replaced annually, compared with maintenance every three to six months for amperometric sensors.The long lifetime of the OptoCap, together with its fast and easy replacement, drasti-cally reduces maintenance costs and the risk of handling errors.Calibration is a quick and straightforward procedure, and in-line calibration within the process is even possible. After calibra-tion, system status information is dis-played on the transmitter in real time, increasing the reliability of the measure-ment point.Plug and Measure The InPro 6970 i features METTLER TOLEDO’s unique Intelligent Sensor Management (ISM ®) technology. ISMprovides an array of features that simplify sensor operations and improve process reliability. All sensor data, including cali-bration history, are stored in the sensor itself. After performing maintenance and calibration, installation in the process is simple. Upon connecting the sensor to an ISM transmitter, such as the M400, allrelevant data is automatically transferred to the transmitter and an oxygen reading is available immediately – no pre-polar-ization is required. Thanks to iSense software that allows ISM sensor calibra-tion in any convenient location, the InPro 6970 i can even be calibrated in advance and stored ready for use, making sensor replacement even quicker and more convenient.Predictive diagnosticsAnother useful ISM feature of the InPro 6970 i and M400 is a set of advanced diagnostics tools. The Dynamic LifetimeIndicator monitors the quality of the OptoCap after each calibration and, to-gether with the current process conditions,calculates and displays on the M400 theremaining lifetime of the OptoCap. Un-scheduled downtime due to sudden failure of the sensing element is therefore avoided.Top performanceThe combination of optical measurement technology, ISM, and METTLER TOLEDO’s years of experience in designing sensors for the brewery industry means that the InPro 6970 i is the most efficient and reli-able oxygen sensor on the market.If you want to reduce costs in your brewing processes, go to:c /InPro6970i c /M400M400 transmitter InPro 6970 i optical oxygen sensorPublisher / Production Mettler-Toledo AG Process Analytics Im Hackacker 15CH-8902 Urdorf Switzerland IllustrationsMettler-Toledo AGSubject to technical changes. © Mettler-Toledo AG 08 /13METTLER TOLEDO Brewery News 213I n P r o 3253 i p H S e n s o rdous challenge for pH sensors. These stress factors can cause a creeping loss of measurement performance and eventu-ally lead to measurement errors, with a negative impact on the hot break process.What are the expectations?In light of these considerations, the life-time of most pH sensors is approximately three months, during which its opera-tional behavior should be continuously monitored and any need for maintenance promptly carried out by the user. In addition, continuous measurement, as opposedto off-line grab sample measurement, provides the possibility of creating a pH profile for every boiling process, i.e., a ’fingerprint’ of the process that can then be used for quality assurance procedures.What is the METTLER TOLEDO solution?For wort kettles with an external boiler, the InPro 3253 i pH sensor can be in-stalled in the boiler piping system using an InTrac 777 retractable housing. For kettles with an internal boiler, direct in-stallation into the kettle is also possible. Tolerance of high temperatures means that the pH sensor can remain in the measuring position during CIP cycles. During long production downtimes, the pipe should be filled with water so that the sensor does not dry out.The compatible multi-parameter / multi-channel M800 transmitter is suitable for either pipe or panel mounting.Why a pH measurement?During wort boiling, protein and hop tan-nins are released which coagulate during the hot break process. Optimal separation of these substances, e.g., through precipi-tation, is important for the stability of the flavor of the beer.Coagulation of the proteins can be im-proved if, at the end of the boiling process, the pH value is reduced to 5 – 5.2. This is achieved by adding mineral acids or by means of biological acidification, i.e., by adding lactic acid. The acidification is regulated through monitoring the pH value.What are the conditions?Temperatures of about 100 °C, high sus-pended solids content, and extreme pH jumps between CIP cycles are a tremen-Robust, Accurate, and Trouble-freeIntelligent pH Measurement for Hot Wort ProcessesOne of the most demanding in-line measurements in a brewery is pH regulation during boiling of the wort. In the past, reliability of the measurement was affected bythe extremely harsh conditions. Robust, modern pH measurement systems that predict their own maintenance offer a dependable, cost-effective solution.InPro 3253 i pH sensor4METTLER TOLEDOBrewery News 21I n P r o 8200 S e n s o rReduced Flocculant Costs at ETPThanks to In-line Turbidity MeasurementTurbidity monitoring is important for liquid / solid separation in waste treatment. A low maintenance, backscatter, turbidity sensor from METTLER TOLEDO is helping a UK brewery to control flocculant dosing at their effluent treatment plant.iron, and magnesium. Commercially available long-chain polymer flocculants, such as modified polyacrylamides, are widely used in wastewater treatment. They usually have a number of functions be-sides flocculation such as break up of emulsified oils in water, pH alteration, and encapsulation of metals. These processes all help to separate solids from the effluent stream by forming a waste sludge that easily precipitates out of the solution. The treated water can then be safely discharged to drain or reused.Flocculation also allows a reduction in process time, which means wastewater can be treated faster and throughput can be increased.In recent times, naturally-based floccu-lants that produce environmentally be-nign floc are becoming increasingly popular, as they help to reduce disposal costs.Why use turbidity?A UK brewery was looking for a way to monitor the levels of flocculants added toFlocculants for wastewater treatmentFlocculants are chemicals that promote the clumping together of substances by causing suspended particles in liquids to aggregate, forming a ’floc’. Use of floc-culants in wastewater treatment is impor-tant for removing contaminants, as they improve the sedimentation or filterability of small particles in the waste stream and thereby ease their removal.Common flocculants often include cat-ionic species such as aluminum, calcium,What are the results?Practice has shown that the InPro 3253 i provides reliable and reproducible values for well over three months, due to its spe-cial membrane glass and self-cleaning diaphragm. Intelligent Sensor Management (ISM ®)diagnostics tools predict when sensor calibration and replacement should be performed. The InTrac 777 retractable housing enables safe removal of the sensor without process interruption.In interaction with the M800 transmitter, the sensor’s operational behavior is con-stantly monitored, and any deviations from plant-typical characteristics are im-mediately reported so that ideal opera-tional performance can be re-established without significant delay.What are the benefits?The sensor’s long lifetime under these demanding measurement conditions re-sults in a significant reduction in costs for replacement sensors.Over and above this, continuous pH mea-surement allows optimal acidification for the extraction of protein and hop tannins,and in the case of biological acidification, even at fluctuating concentrations of lactic acid in the batch tank. Operational behavior and availability of the measurement point are significantly improved by ISM’s diagnostics features.Find out more about the InPro 3253 i at:c /InPro3250METTLER TOLEDO Brewery News 215wastewater so that it could be dosed cor-rectly and prevent wasteful over-dosing and potentially ineffective under-dosing. The turbidity sensor would also be used for monitoring the efficacy of the flocculants to ensure they were producing the desired effect. METTLER TOLEDO was asked to provide a solution.Turbidity is the ideal measurement for this application, as the resulting flocs from turbid sediments can easily be measured using backscatter turbidity techniques. METTLER TOLEDO backscatter turbidity sensors have a wide measurement range that provides great application flexibility. In addition, these low maintenance and robust sensors are particularly beneficial for use in continuous and often unman-ned processes, such as those at ETP installations.Low-maintenance solutionThe brewery required a sensor suitable for medium to high levels of total suspended solids (15 g / l) that could be retracted from a pipe installation to allow easy sensor cleaning whilst the process was still running.The supplied METTLER TOLEDO system comprised the InPro 8200 turbidity sensor, InTrac 779 e retractable housing, and Trb 8300 transmitter. The InPro 8200sensor is a dual optical fiber turbidity sen-sor that is designed for a wide variety of industrial applications, including liquid /solid separation. Due to the nature of the brewery’s process, it was important that the sensor be resistant to fouling and easy to maintain. The InPro 8200 was there-fore a wise choice, as it requires little maintenance and has a uniform struc-ture that reduces fouling on its scratch-resistant sapphire window. This prevents build-up of contaminants, allowing error-free measurement.Combined with the InTrac 779 e retract-able housing with integral flushing chamber, our customer is able to retractthe sensor at regular intervals and cleanor calibrate the sensor without interrupt-ing the process.Reduced costsBy installing the InPro 8200 turbidity sensor with the Trb 8300 transmitter and InTrac 779 e retractable housing, the brewery is now able to monitor the dosing of flocculants with precision and ease. This has helped to reduce costs as only the necessary amount of flocculant is added. Consequently, the process has becomemore efficient as throughput of the efflu-ent treatment plant has been increased.If you want to reduce your effluent treat-ment costs, visit:c/turbInPro 8200 turbidity sensor Trb 8300 transmitter6METTLER TOLEDO Brewery News 21iRO with sensorsystems, for temporary in-line analytical measurement. iRO (which stands foracquisition is required. Plug and Measure functionality, a feature of our ISM technology, ensures error-free commis-sioning. While Bluetooth communication for data read out and system configura-tion sets a new standard in ease of use.Here, we look at three uses for iRO that will save you both time and money.Process optimizationDuring process development and optimization of production processes, in-line measurement of analytical parameters, such as pH, oxygen concentration, and conductivity, is often vital. Finding the most suitable in-stallation points for analytical instruments can be a long and complex process if complete measuring systems have to be installed temporarily.The iRO data logger is easy to commission, as it needs no wiring and thus simplifies short-term data acquisition. Measurements from up to two sensors can be logged for several months, and data read out with a computer over a Bluetooth connection can be performedrdate and time, and important sensor de-tails such as serial number and diagnostics information.Quality assuranceQuality managers need data. The trace-ability of process parameters at different measurement guaranteeing production process and compliance with validation requirements. The iRO tempo-rary data logger is able to provide addi-tional measurement points, without the need for complicated installation.TroubleshootingIn processes such as filtration and filling, oxygen reduce final contamination, various positions is necessary. Installation of a complete measurement system needs wiring and connection to the control sys-tem. iRO is the perfect tool for these situ-ations. No wiring is needed and the data can be read out at any time. Data acquisi-tion achieved.Discover more reasons to use iRO, at:c /iROP a p e r sGreater Process Reliability Discover Moreand Increase Your Brewery’s Efficiency8METTLER TOLEDO Brewery News 21V i s i o n I n s p e c t i o n S y s t e m sPremium Brands Benefitfrom 100 % Packaging ConfidenceFor an established wine company, presentation and product quality are crucial to its success. These are both factors they do not want to jeopardize. By using a vision inspection system, this manufacturer has 100 % confidence in its product quality, ensuring brand reputation is maintained.Inspection priorityTWG’s greatest inspection need is ensur-ing accuracy of label application. Label presence and quality is essential for up-holding the brand reputation. According to Wine Marketing Consultants, “A brand is an idea, and if perceptions by anyone interacting with the product are negativethe strength of the brand will suffer and brand equity will be lost.”Prevention is keyIn one instance, CI-Vision’s label in-spection system prevented wrong labels from being applied on up to 1000 cases. Thanks to the system’s accurate speci-fications, TWG was able to prevent a potential liability. With an average pro-Producers of the world famous Franzia ® and the sensational Cupcake ® Vineyards brand, The Wine Group, Inc. (TWG) uses vision inspection on its production lines. This ensures high quality in filling accu-racy, packaging and bottling presentation. This technology also has the advantage of automated checking, rather than manual inspection. Therefore, cases are produced more efficiently with improved quality.A need for accuracy and reliabilityIts widely recognized brands could be se-verely diminished with the distribution of just one batch of defective product. Not only this, inappropriately filled bottles go against standards, which are regulated by industry specifications.A confident choiceTWG chose to implement vision inspection systems into its production lines instead of manual inspectors. By utilizing vision inspection technology, any errors caused by manual inspection have been stopped, ensuring overall product quality. Also, substituting manual inspectors has led to additional labor resources being used in other quality control initiatives within the facility.With production speeds of 200 bpm run-ning through the labeler, manual inspec-tion became nearly impossible. CI-Visionis able to accurately inspect at speeds of 200 bpm and greater. TWG’s vision inspec-tion solution currently performs the job of what normally requires six quality inspec-tors. CI-Vision designed TWG’s two solu-tions according to the needs of the wine manufacturer.Complete protection The first station is installed directly after the filler, with inspection of correct fillheight, presence of cap, screw cap, and cork, with the majority of defects occur-ring during the capsules process. Station two is found directly after the labeler and consists of three cameras inspecting for the presence of capsule, front and backlabel, and correct product registration. Bottle top inspectionMETTLER TOLEDO Brewery News 219duction turnover of 30 million bottles on a single line, reliable inspections that never tire are essential for successful production and brand integrity.Vision trainingAs a part of a vision inspection program at CI-Vision, expert training is provided to customers and line operators by vision experts, making ownership of the solution easy and efficient. Using their knowledge gained from the training courses, opera-tors are able to challenge the system to always ensure its accuracy. Once systems are product trained and quickly tested for accuracy, they run efficiently on their own and inspections no longer become a concern to manufacturers.* TWG brands and case study used with the express written permission of The Wine Group, Inc.c /civisionVision inspection systems on the production line at The Wine Group, ensuring labels are straight and legible, seals are safe and secure, and that bottles are filled accurately.sensorVisit for more information /pro Get in-line with METTLER TOLEDOIntelligent Sensor Management for Brewing ProcessesISM ® is METTLER TOLEDO’s digital technology platform forprocess analytical measurement systems. With ISM solutions,maintenance becomes predictable, sensor handling is simple,and process uptime is increased.See the complimentary brochure, white papers, and softwareon our website for the brewery industry and discover how ISMdelivers:Greater process reliabilityEasy sensor handlingReduced maintenancec w/ISM-breweryMettler-Toledo Ingold, Inc.36 Middlesex TurnpikeBedford, MA 01730, USATel: +1 781 301 8800Fax: +1 781 271 0681Toll Free: +1 800 352 8763Email: **************。

从禁到限的改变带给我们怎样的思考作文

从禁到限的改变带给我们怎样的思考作文英文版：The Transition from Prohibition to Restriction: Reflections on Its ImplicationsThe shift from prohibition to restriction, a significant transformation in social and policy landscapes, presents us with profound considerations. This transition is not merely a semantic change, but a reflection of evolving societal perspectives and evolving understandings of complex issues.Prohibition, by its nature, is absolute and unyielding. It is the categorical denial of something, often with the aim of eradicating it entirely. However, history has shown us that prohibition often leads to unintended consequences, such as the creation of black markets, increased criminal activity, and a sense of resentment among those affected. This is because prohibition fails to address the root causes of the behavior it aims to suppress.On the other hand, restriction is a more nuanced approach. It involves setting limits or boundaries, allowing for some degree of flexibility and accommodation. Restrictions can be tailored to specific contexts and situations, taking into account various factors such as social, cultural, and economic realities. They aim to balance different interests and perspectives, while also acknowledging that certain behaviors may be unacceptable or harmful in certain contexts.The move from prohibition to restriction suggests a shift towards a more nuanced and comprehensive understanding of complex issues. It recognizes that blanket bans are not always effective, and that a more nuanced approach is needed to address the root causes of problematic behaviors. This shift also reflects a recognition of the importance of balancing different interests and perspectives, and the need for society to find ways to accommodate diverse viewpoints and behaviors.However, the transition from prohibition to restriction is not without its challenges. Implementing restrictions requirescareful consideration and planning, to ensure that they are fair, effective, and sustainable. It also requires a willingness to engage in difficult conversations and make compromises, in order to find common ground and build consensus.In conclusion, the shift from prohibition to restriction represents a significant evolution in our approach to complex issues. It calls for a more nuanced understanding of the issues involved, a recognition of the need to balance different interests and perspectives, and a willingness to engage in difficult conversations and make compromises. As we navigate this transition, it is important to remember that the goal is not simply to replace one policy with another, but to create a more inclusive, understanding, and effective approach to addressing the challenges we face.中文版：从禁到限的改变带给我们怎样的思考从禁止到限制的转变，在社会和政策领域中呈现出深刻的思考。

Elementary+school+English+declarative+sentences

Future tense
Future Simple
They will visit their grandparents next week
Future Continuous
We will be studying next year
Future Perfect
They will have finished their work by the end of the month
Subject+predict+direct object+direct object
要点一
Summary word
要点二
Detailed description
Extended sentence structure
In more complex declarative sentences, indirect and direct objects may be included, such as "He gave his friend a book." In this sentence structure, both indirect and direct objects follow the predicate, and the direct object is usually marked with a preposition or article.
2024-01-02
Elementary school English declarative sentences
汇报人：
目录
• The definition and characteristics of declarative intentions

Renault Tribler生活随时起跑说明书

life on demandRenault Triber is everything you need from a seven-seater car. Modular, efficient and practical, it fits perfectly in your everyday life.With its dual tone design, advanced connectivity and enhanced safety pack, Renault Triber is yourcompanion for the city and beyond.enhanced driving assistance systems 20.32 cm touchscreen mediaNAV with Apple CarPlay & Android AutoIndia’s safest 7–seater*modular from 5 to 7 seats modular with 100+ seat combinations up to 625L boot space01.design02.modularity03.driving comfort04.advanced driving assistance systems 05.customizationinteractive menu301.designlooks the partRenault Triber stands tall with fresh, muscular look, comfortable, spacious interior and a range of customizable dual tone options. Every detail, from the 15” styled flex wheels* to the LED turn indicators, is smartly designed to makeRenault Triber the go-to choice.*for RXZ4switch it upWith space for up to seven people, the removable third row of seats and 625l of trunk space*, Triber’s ultra-modular interior gives you comfort, flexibility and a lot of storage possibilities.02.modularityWith modularity to go from 5 to 7 seats and over 100 possible seating combinations, Renault Triber gives you all the space you need for your lifestyle.mode 5-seatermode 7-seaterfeeling goodTriber’s sophisticated, ergonomic and spacious cabin means you and your family can focus on enjoying the ride. From the 20.32 cm touchscreen mediaNAV with Apple CarPlay™ & Android Auto™, to the air conditioning and hands-free access, it’s got it all.Renault Triber has an internal storage of 23.34 liters, including refrigerated console which keeps food and beverages cool during short or long trips, for your utmost comfort.03.driving comfortDual tone dashboard & multimedia screen with smartphone replicationrefrigerated central storage*for RXT and RXZ Android Auto™ is a Google Inc. brand.Apple CarPlay™ is a trademark of Apple Inc.explore more →menu ↑9 advanced driving assistance systemsAs part of the human first program and in compliance with BS6 step 2* norms, Renault Triber is equipped with nine innovative advanced driving assistance systems.04. advanced driving assistance systems new electronic stability program Automatically corrects your car’s trajectory so you avoid dangerous skids.rear parking sensor Ultrasonic sensors in the rear bumper measure the distance between the vehicle and an obstacle.new traction control system Limits wheel slip during starting, acceleration and braking.airbag Four airbags offer * increased protection.new hill start assist Maintains brake pressure for two seconds, preventing rollback when you move away on a steep slope.new tyre pressure monitoring system The tyre pressure monitoring system displays the tyre pressure status in real time with a pictogram on the dashboard. Always know the condition of your tires.driving assistance• ABS + EBD • new electronic stability program • front airbags • new traction control systemparking assistance• r ear parking sensors security assistance • brake assist • new tyre pressure monitoring system • load limiter + pretensioner (driver only)7*4 airbag available in RXZ onlyexplore more →menu ↑color palettemoonlight silver metal mustardice cool white electric bluecedar browndual tone color palettemoonlight silver with mystery black roof metal mustard with mystery black roofice cool white with mystery black roof electric blue with mystery black roofcedar brown with mystery black roof* dual tone colours onlyavailable in RXZ*moonlight silver & ice cool whiteonly available in RXE*photos not contractually bindingexplore more →menu ↑interior trimsRXE• wheel centre cap• LED instrument cluster - white colour • 12V socket - 1st row only• speed alert warningRXL=RXE+• full plastic wheel cover• ORVM – manual internal adjust• speed sensing door lockRXT=RXL+• LED turn indicator on ORVMs• japda fabric upholstery• ORVM - electrical adjustRXZ=RXT+• LED DRLs• stylish akaza fabric upholstery• 12V socket - 3rd row• 2 side airbags (front seats)upholstery wheel rims meson black fabric japda fabric stylish akaza fabric wheel centre cap full plastic wheel coverstyled flex wheel explore more →10accessories05. customizationilluminated logoAdd character to your Triber by fitting and flaunting a lit-up Renault logo on its back.roof carrierA bolder presence and lots of extra space – that’s what the solid roof rackcarries along.alloy wheelsThe subtle and remarkable silver alloys add a style element to the car.chrome garnish on front grilleFirst impressions matter so make it a lot more stunning with chrome accentson the grille.seat coversEnhance the cabin look with a range of seat covers.explore more →menu ↑11dimensionsand volumesexplore more →*except RXZ1213RXERXLRXTRXZenergy MTenergy MTenergy MT & EASY-Renergy MT & EASY-R999372 @ 6,25096 @ 3,5005-speed MT 5-speed MT 5-speed MT& Easy-R AMT5-speed MT & Easy-R AMTmulti point fuel injectionelectric power steeringMacPherson strut with lower triangle & coil springtorsion beam axledisc drum165 / 80165 / 80165 / 80185/6535.5635.5635.5638.13,9901,7391,6431,5471,5471,5471,5271,5451,5451,5451,52540182625engine & transmissiondisplacementnumber of cylindersmaximum power output (ps @ rpm)maximum torque (N.m @ rpm)transmission typefuel system steering typesuspension front rear brake front rearwheels and tyres tyre (mm)wheel rim (cm)dimensions & capacities overall length (mm)overall width without mirrors (mm)overall height without roof rails (mm)front track (mm)rear track (mm)fuel tank capacity (litres)ground clearence (mm)boot space (l)mode 5 seater mode 7 seater84engines14comfort (following)front seat back pocket – driver side---•rear wiper, washer & defogger---•auto up down – driver window---•rear view camera---•12V socket - 3rd row---•safetyfront airbag – driver and passenger ••••ABS + EBD with brake assist••••electronic stability program new (ESP)••••tyre pressure monitoring system new (TPMS)••••traction control system new (TCS)••••hill start assist new (HSA)••••load limiter + pretensioner (driver only)••••speed alert warning••••seat belt reminder – driver + passenger••••rear parking sensors••••pedestrian protection••••speed sensing door lock-•••impact sensing unlock-•••2 side airbags (front seats)---•• = standard. - = not available.15the human first program is a comprehensive safetyprogramme developed by Renault in collaboration with researchers, experts and fire-fighters.because road safety is the business of all road users - be theypedestrians, cyclists or motorists - the human first program by Renault undertakes to:find out more about the human first program1.prevent accidents by developing safety equipment and advanced driving and safety assistance systemsup to 36 advanced driving assistance systems / more than60 safety systems, up to 7 airbags, child seats (Isofix), Renault’s Fixe4sure solution / more than 2,000 safety-related patents filed since 19702.reduce the number of accidents and their severity by investing massively in R&Dsafety score / safety coach / connected services / big data /artificial intelligence and cybersecurity systems16Renault careserviceWe are always by your side to make your driving experience easy and save you time maintaining your Renault. We’ll give you online estimates and appointments, service packages, maintenance contracts, insurance, assistance, the My Renault program and more simple, easy solutions perfectly tailored to your needs.find out more about Renault care service17locate a dealer →accessories/features shown may not be part of the standard fitment. the registration plate is licensed with Renault Group Paris. Renault India Pvt Ltd reserves the right to sale of Renault Triber in India. every precaution has been taken to ensure that this publication is accurate and up to date on the date it is published. this document has been created on the basis of pilot lots and prototypes. as part of its ongoing product improvement policy, Renault India Pvt. Ltd. reserves the right to modify the specifications and vehicles described and shown at any time. such modifications are communicated to Renault dealers as quickly as possible. depending on the country of sale, certain versions may differ and certain equipments may be unavailable (as standard, optional or accessory). the colours that appear on the website may differ slightly from the actual paint or upholstery colours. RXE version available in ice cool white and moonlight silver only. Triber has scored 4-star safety rating for adult occupant safety and 3-star child occupant safety in crash test conducted by Global NCAP. the same has been published by NCAP on their website. the evaluation of the tests by Global NCAP has resulted in Triber being the safest in the 7-seater mass segment in India. please contact your nearest dealer for the latest information. all rights are reserved. the reproduction in any format and by any means of all or part of this publication without prior written authorisation from Renault is prohibited. segment definition based on Renault internal classification. *BS6 step 2 compliant (as per Gazette of India REGD. NO. D. L.-33004/99 norms). our customer service team is available on our toll-free number from Monday to Sunday, between 07:00 am to 11:00 pm.www.renault.co.in Call:180****444418Renault recommends。

1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。